| Demographic Characteristic | No or Minimal (2023) |
No or Minimal (2024) |
Mild (2023) |
Mild (2024) |
Moderate (2023) |
Moderate (2024) |
Moderate or Severe (2023) |
Moderate or Severe (2024) |
Severe (2023) |
Severe (2024) |
|---|---|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 15,072 | -- | 6,003 | -- | 2,740 | -- | 4,876 | -- | 2,136 |
| AGE GROUP | ||||||||||
| 12-13 | -- | 5,166 | -- | 1,693 | -- | 674 | -- | 1,236 | -- | 563 |
| 14-15 | -- | 4,997 | -- | 2,090 | -- | 993 | -- | 1,778 | -- | 785 |
| 16-17 | -- | 4,909 | -- | 2,219 | -- | 1,073 | -- | 1,863 | -- | 789 |
| SEX | ||||||||||
| Male | -- | 9,296 | -- | 2,559 | -- | 898 | -- | 1,420 | -- | 522 |
| Female | -- | 5,776 | -- | 3,444 | -- | 1,842 | -- | 3,456 | -- | 1,614 |
| HISPANIC ORIGIN AND RACE | ||||||||||
| Not Hispanic or Latino | -- | 10,924 | -- | 4,488 | -- | 1,999 | -- | 3,637 | -- | 1,639 |
| AIAN | -- | 138 | -- | 37 | -- | 17 | -- | 34 | -- | 17 |
| Asian | -- | 968 | -- | 312 | -- | 150 | -- | 234 | -- | 84 |
| Black or African American | -- | 2,213 | -- | 790 | -- | 357 | -- | 567 | -- | 210 |
| NHPI | -- | * | -- | * | -- | * | -- | * | -- | * |
| White | -- | 7,025 | -- | 3,073 | -- | 1,343 | -- | 2,533 | -- | 1,190 |
| Two or More Races | -- | 526 | -- | 253 | -- | 127 | -- | 263 | -- | 137 |
| Hispanic or Latino | -- | 4,148 | -- | 1,515 | -- | 741 | -- | 1,239 | -- | 498 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: GAD symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD; 5 to 9 = mild symptoms; 10 to 14 = moderate symptoms; 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||
| Demographic Characteristic | No or Minimal (2023) |
No or Minimal (2024) |
Mild (2023) |
Mild (2024) |
Moderate (2023) |
Moderate (2024) |
Moderate or Severe (2023) |
Moderate or Severe (2024) |
Severe (2023) |
Severe (2024) |
|---|---|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 58.1 | -- | 23.1 | -- | 10.6 | -- | 18.8 | -- | 8.2 |
| AGE GROUP | ||||||||||
| 12-13 | -- | 63.8 | -- | 20.9 | -- | 8.3 | -- | 15.3 | -- | 7.0 |
| 14-15 | -- | 56.4 | -- | 23.6 | -- | 11.2 | -- | 20.1 | -- | 8.8 |
| 16-17 | -- | 54.6 | -- | 24.7 | -- | 11.9 | -- | 20.7 | -- | 8.8 |
| SEX | ||||||||||
| Male | -- | 70.0 | -- | 19.3 | -- | 6.8 | -- | 10.7 | -- | 3.9 |
| Female | -- | 45.6 | -- | 27.2 | -- | 14.5 | -- | 27.3 | -- | 12.7 |
| HISPANIC ORIGIN AND RACE | ||||||||||
| Not Hispanic or Latino | -- | 57.3 | -- | 23.6 | -- | 10.5 | -- | 19.1 | -- | 8.6 |
| AIAN | -- | 66.1 | -- | 17.8 | -- | 8.0 | -- | 16.1 | -- | 8.1 |
| Asian | -- | 64.0 | -- | 20.6 | -- | 9.9 | -- | 15.5 | -- | 5.6 |
| Black or African American | -- | 62.0 | -- | 22.1 | -- | 10.0 | -- | 15.9 | -- | 5.9 |
| NHPI | -- | * | -- | * | -- | * | -- | * | -- | * |
| White | -- | 55.6 | -- | 24.3 | -- | 10.6 | -- | 20.1 | -- | 9.4 |
| Two or More Races | -- | 50.5 | -- | 24.3 | -- | 12.1 | -- | 25.3 | -- | 13.1 |
| Hispanic or Latino | -- | 60.1 | -- | 21.9 | -- | 10.7 | -- | 18.0 | -- | 7.2 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: GAD symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD; 5 to 9 = mild symptoms; 10 to 14 = moderate symptoms; 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||
| Geographic/Socioeconomic Characteristic | No or Minimal (2023) |
No or Minimal (2024) |
Mild (2023) |
Mild (2024) |
Moderate (2023) |
Moderate (2024) |
Moderate or Severe (2023) |
Moderate or Severe (2024) |
Severe (2023) |
Severe (2024) |
|---|---|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 15,072 | -- | 6,003 | -- | 2,740 | -- | 4,876 | -- | 2,136 |
| GEOGRAPHIC REGION | ||||||||||
| Northeast | -- | 2,328 | -- | 970 | -- | 449 | -- | 782 | -- | 332 |
| Midwest | -- | 3,159 | -- | 1,237 | -- | 550 | -- | 1,014 | -- | 463 |
| South | -- | 6,113 | -- | 2,304 | -- | 1,039 | -- | 1,907 | -- | 868 |
| West | -- | 3,472 | -- | 1,492 | -- | 701 | -- | 1,174 | -- | 473 |
| COUNTY TYPE | ||||||||||
| Large Metro | -- | 8,677 | -- | 3,321 | -- | 1,512 | -- | 2,690 | -- | 1,178 |
| Small Metro | -- | 4,698 | -- | 2,051 | -- | 926 | -- | 1,618 | -- | 692 |
| Nonmetro | -- | 1,697 | -- | 630 | -- | 303 | -- | 569 | -- | 266 |
| Urbanized | -- | 696 | -- | 229 | -- | 131 | -- | 212 | -- | 80 |
| Less Urbanized | -- | 874 | -- | 347 | -- | 145 | -- | 301 | -- | 156 |
| Completely Rural | -- | 127 | -- | 54 | -- | 26 | -- | 56 | -- | 30 |
| POVERTY LEVEL | ||||||||||
| Less Than 100% | -- | 3,411 | -- | 1,122 | -- | 542 | -- | 985 | -- | 442 |
| 100-199% | -- | 3,121 | -- | 1,264 | -- | 524 | -- | 935 | -- | 411 |
| 200% or More | -- | 8,540 | -- | 3,617 | -- | 1,674 | -- | 2,956 | -- | 1,283 |
| HEALTH INSURANCE1 | ||||||||||
| Private | -- | 8,338 | -- | 3,440 | -- | 1,647 | -- | 2,865 | -- | 1,217 |
| Medicaid/CHIP | -- | 6,162 | -- | 2,302 | -- | 1,067 | -- | 1,985 | -- | 918 |
| Other2 | -- | 793 | -- | 340 | -- | 166 | -- | 249 | -- | 84 |
| No Coverage | -- | 755 | -- | 293 | -- | 80 | -- | 160 | -- | 80 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: GAD symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD; 5 to 9 = mild symptoms; 10 to 14 = moderate symptoms; 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater. 1 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 2 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||
| Geographic/Socioeconomic Characteristic | No or Minimal (2023) |
No or Minimal (2024) |
Mild (2023) |
Mild (2024) |
Moderate (2023) |
Moderate (2024) |
Moderate or Severe (2023) |
Moderate or Severe (2024) |
Severe (2023) |
Severe (2024) |
|---|---|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 58.1 | -- | 23.1 | -- | 10.6 | -- | 18.8 | -- | 8.2 |
| GEOGRAPHIC REGION | ||||||||||
| Northeast | -- | 57.1 | -- | 23.8 | -- | 11.0 | -- | 19.2 | -- | 8.1 |
| Midwest | -- | 58.4 | -- | 22.9 | -- | 10.2 | -- | 18.7 | -- | 8.6 |
| South | -- | 59.2 | -- | 22.3 | -- | 10.1 | -- | 18.5 | -- | 8.4 |
| West | -- | 56.6 | -- | 24.3 | -- | 11.4 | -- | 19.1 | -- | 7.7 |
| COUNTY TYPE | ||||||||||
| Large Metro | -- | 59.1 | -- | 22.6 | -- | 10.3 | -- | 18.3 | -- | 8.0 |
| Small Metro | -- | 56.1 | -- | 24.5 | -- | 11.1 | -- | 19.3 | -- | 8.3 |
| Nonmetro | -- | 58.6 | -- | 21.8 | -- | 10.5 | -- | 19.6 | -- | 9.2 |
| Urbanized | -- | 61.2 | -- | 20.1 | -- | 11.6 | -- | 18.6 | -- | 7.1 |
| Less Urbanized | -- | 57.4 | -- | 22.8 | -- | 9.5 | -- | 19.8 | -- | 10.2 |
| Completely Rural | -- | 53.6 | -- | 22.8 | -- | 11.0 | -- | 23.6 | -- | 12.6 |
| POVERTY LEVEL | ||||||||||
| Less Than 100% | -- | 61.8 | -- | 20.3 | -- | 9.8 | -- | 17.8 | -- | 8.0 |
| 100-199% | -- | 58.7 | -- | 23.8 | -- | 9.8 | -- | 17.6 | -- | 7.7 |
| 200% or More | -- | 56.5 | -- | 23.9 | -- | 11.1 | -- | 19.6 | -- | 8.5 |
| HEALTH INSURANCE1 | ||||||||||
| Private | -- | 56.9 | -- | 23.5 | -- | 11.3 | -- | 19.6 | -- | 8.3 |
| Medicaid/CHIP | -- | 59.0 | -- | 22.0 | -- | 10.2 | -- | 19.0 | -- | 8.8 |
| Other2 | -- | 57.3 | -- | 24.6 | -- | 12.0 | -- | 18.0 | -- | 6.0 |
| No Coverage | -- | 62.5 | -- | 24.2 | -- | 6.7 | -- | 13.3 | -- | 6.6 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: GAD symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD; 5 to 9 = mild symptoms; 10 to 14 = moderate symptoms; 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater. 1 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 2 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||
| Demographic Characteristic | Had MDE1,2 (2023) |
Had MDE1,2 (2024) |
Had MDE with Severe Impairment1,3,4 (2023) |
Had MDE with Severe Impairment1,3,4 (2024) |
|---|---|---|---|---|
| TOTAL | 4,517b | 3,840 | 3,358b | 2,834 |
| AGE GROUP | ||||
| 12-13 | 896 | 767 | 618 | 567 |
| 14-15 | 1,682a | 1,366 | 1,287b | 1,000 |
| 16-17 | 1,939 | 1,706 | 1,453 | 1,267 |
| SEX | ||||
| Male | 1,207 | 1,082 | 845 | 735 |
| Female | 3,310b | 2,758 | 2,513b | 2,099 |
| HISPANIC ORIGIN AND RACE | ||||
| Not Hispanic or Latino | 3,348b | 2,824 | 2,491b | 2,055 |
| AIAN | 41 | 17 | 18 | 12 |
| Asian | 193 | 172 | 128 | 135 |
| Black or African American | 458 | 364 | 343 | 260 |
| NHPI | * | * | * | * |
| White | 2,431b | 2,048 | 1,823b | 1,483 |
| Two or More Races | 217 | 222 | 174 | 163 |
| Hispanic or Latino | 1,169 | 1,016 | 867 | 779 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Respondents with unknown past year major depressive episode (MDE) data were excluded. 3 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 4 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||
| Demographic Characteristic | Had MDE1,2 (2023) |
Had MDE1,2 (2024) |
Had MDE with Severe Impairment1,3,4 (2023) |
Had MDE with Severe Impairment1,3,4 (2024) |
|---|---|---|---|---|
| TOTAL | 18.1b | 15.4 | 13.5b | 11.3 |
| AGE GROUP | ||||
| 12-13 | 11.9 | 10.1 | 8.2 | 7.4 |
| 14-15 | 19.1a | 16.0 | 14.6a | 11.7 |
| 16-17 | 22.7b | 19.3 | 17.0a | 14.3 |
| SEX | ||||
| Male | 9.4 | 8.4 | 6.6 | 5.7 |
| Female | 27.3b | 22.6 | 20.8b | 17.2 |
| HISPANIC ORIGIN AND RACE | ||||
| Not Hispanic or Latino | 18.2b | 15.4 | 13.5b | 11.2 |
| AIAN | 18.2 | 8.6 | 8.2 | 6.1 |
| Asian | 13.7 | 11.9 | 9.1 | 9.4 |
| Black or African American | 13.3 | 10.5 | 10.0a | 7.5 |
| NHPI | * | * | * | * |
| White | 19.6b | 16.8 | 14.7b | 12.2 |
| Two or More Races | 24.4 | 22.2 | 19.6 | 16.4 |
| Hispanic or Latino | 18.0 | 15.4 | 13.3 | 11.8 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Respondents with unknown past year major depressive episode (MDE) data were excluded. 3 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 4 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||
| Geographic/Socioeconomic Characteristic | Had MDE1,2 (2023) |
Had MDE1,2 (2024) |
Had MDE with Severe Impairment1,3,4 (2023) |
Had MDE with Severe Impairment1,3,4 (2024) |
|---|---|---|---|---|
| TOTAL | 4,517b | 3,840 | 3,358b | 2,834 |
| GEOGRAPHIC REGION | ||||
| Northeast | 623 | 563 | 482 | 449 |
| Midwest | 1,063b | 818 | 792b | 579 |
| South | 1,769a | 1,482 | 1,324a | 1,108 |
| West | 1,061 | 976 | 760 | 698 |
| COUNTY TYPE | ||||
| Large Metro | 2,609b | 1,968 | 1,952b | 1,475 |
| Small Metro | 1,317 | 1,401 | 951 | 1,019 |
| Nonmetro | 591 | 470 | 455a | 339 |
| Urbanized | 210 | 187 | 163 | 138 |
| Less Urbanized | 338a | 239 | 258a | 164 |
| Completely Rural | * | 45 | 35 | 37 |
| POVERTY LEVEL | ||||
| Less Than 100% | 813 | 765 | 612 | 567 |
| 100-199% | 958a | 768 | 741 | 607 |
| 200% or More | 2,746b | 2,307 | 2,006b | 1,660 |
| HEALTH INSURANCE5 | ||||
| Private | 2,566a | 2,218 | 1,895a | 1,633 |
| Medicaid/CHIP | 1,784 | 1,581 | 1,351 | 1,206 |
| Other6 | 310b | 163 | 253b | 111 |
| No Coverage | 169 | 149 | 127 | 96 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Respondents with unknown past year major depressive episode (MDE) data were excluded. 3 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 4 Respondents with unknown MDE data or unknown impairment data were excluded. 5 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 6 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||
| Geographic/Socioeconomic Characteristic | Had MDE1,2 (2023) |
Had MDE1,2 (2024) |
Had MDE with Severe Impairment1,3,4 (2023) |
Had MDE with Severe Impairment1,3,4 (2024) |
|---|---|---|---|---|
| TOTAL | 18.1b | 15.4 | 13.5b | 11.3 |
| GEOGRAPHIC REGION | ||||
| Northeast | 15.9 | 14.4 | 12.3 | 11.5 |
| Midwest | 20.4b | 15.8 | 15.2b | 11.2 |
| South | 17.9b | 14.8 | 13.4a | 11.1 |
| West | 17.9 | 16.6 | 12.8 | 11.9 |
| COUNTY TYPE | ||||
| Large Metro | 19.1b | 14.0 | 14.3b | 10.5 |
| Small Metro | 16.6 | 17.3 | 12.0 | 12.6 |
| Nonmetro | 18.1 | 16.7 | 14.0 | 12.1 |
| Urbanized | 17.9 | 16.7 | 13.9 | 12.4 |
| Less Urbanized | 18.8 | 16.2 | 14.4 | 11.2 |
| Completely Rural | * | 19.8 | 11.6 | 16.4 |
| POVERTY LEVEL | ||||
| Less Than 100% | 15.0 | 14.4 | 11.3 | 10.7 |
| 100-199% | 18.6a | 15.0 | 14.4 | 11.9 |
| 200% or More | 19.1b | 15.8 | 14.0b | 11.4 |
| HEALTH INSURANCE5 | ||||
| Private | 18.9b | 15.7 | 14.0b | 11.6 |
| Medicaid/CHIP | 17.1 | 15.7 | 12.9 | 12.0 |
| Other6 | 22.8b | 12.1 | 18.6b | 8.3 |
| No Coverage | 14.4 | 12.9 | 10.9 | 8.3 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Respondents with unknown past year major depressive episode (MDE) data were excluded. 3 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 4 Respondents with unknown MDE data or unknown impairment data were excluded. 5 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 6 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||
| Type/Location of Treatment or Other Services | Aged 12-17 (2023) |
Aged 12-17 (2024) |
Aged 12-13 (2023) |
Aged 12-13 (2024) |
Aged 14-15 (2023) |
Aged 14-15 (2024) |
Aged 16-17 (2023) |
Aged 16-17 (2024) |
|---|---|---|---|---|---|---|---|---|
| MENTAL HEALTH TREATMENT OR OTHER SERVICES1 | -- | 7,874 | -- | 2,496 | -- | 2,647 | -- | 2,731 |
| MENTAL HEALTH TREATMENT | -- | 7,393 | -- | 2,312 | -- | 2,520 | -- | 2,561 |
| Inpatient | -- | 736 | -- | 220 | -- | 238 | -- | 279 |
| Hospital | -- | 579 | -- | 161 | -- | 185 | -- | 233 |
| Residential Mental Health Treatment Center | -- | 417 | -- | 120 | -- | 159 | -- | 138 |
| Residential Drug or Alcohol Rehab or Treatment Center | -- | 127 | -- | 38 | -- | 67 | -- | 22 |
| Some Other Place as an Inpatient | -- | 175 | -- | 74 | -- | 50 | -- | 51 |
| Outpatient | -- | 5,525 | -- | 1,741 | -- | 1,849 | -- | 1,936 |
| Mental Health Treatment Center | -- | 820 | -- | 221 | -- | 312 | -- | 287 |
| Drug or Alcohol Rehab or Treatment Center | -- | 92 | -- | 13 | -- | 47 | -- | 32 |
| Office of a Therapist, Psychologist, Psychiatrist, or Mental Health Professional | -- | 3,509 | -- | 954 | -- | 1,180 | -- | 1,375 |
| General Medical Clinic or Doctor’s Office | -- | 1,779 | -- | 431 | -- | 654 | -- | 693 |
| Hospital | -- | 458 | -- | 98 | -- | 176 | -- | 184 |
| School’s Health or Counseling Center | -- | 2,941 | -- | 1,092 | -- | 981 | -- | 868 |
| Some Other Place as an Outpatient | -- | 263 | -- | 71 | -- | 119 | -- | 72 |
| Outpatient, Other Than General Medical Clinic or Doctor’s Office | -- | 5,170 | -- | 1,646 | -- | 1,714 | -- | 1,810 |
| Prescription Medication | 3,604 | 3,343 | 955 | 883 | 1,293 | 1,167 | 1,355 | 1,293 |
| Telehealth Treatment2 | 3,677 | 3,389 | 848 | 941 | 1,410a | 1,164 | 1,419 | 1,283 |
| Prison, Jail, or Juvenile Detention Center | 314 | 312 | 104 | 97 | 106 | 121 | 103 | 93 |
| OTHER SERVICES | ||||||||
| Support Services | ||||||||
| Support Group | 1,926 | 1,745 | 565 | 691 | 775b | 522 | 586 | 533 |
| Peer Support Specialist or Recovery Coach | 820 | 793 | 181 | 260 | 327 | 255 | 313 | 278 |
| Emergency Room/Department | 706 | 684 | 210 | 208 | 284 | 208 | 212 | 268 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple types/locations for receiving mental health treatment or other services; thus, these response categories are not mutually exclusive. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Other services include treatment for mental health, emotions, or behavior through support group services; peer support specialist or recovery coach services; or treatment received in an emergency room/department. 2 Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Type/Location of Treatment or Other Services | Aged 12-17 (2023) |
Aged 12-17 (2024) |
Aged 12-13 (2023) |
Aged 12-13 (2024) |
Aged 14-15 (2023) |
Aged 14-15 (2024) |
Aged 16-17 (2023) |
Aged 16-17 (2024) |
|---|---|---|---|---|---|---|---|---|
| MENTAL HEALTH TREATMENT OR OTHER SERVICES1 | -- | 30.3 | -- | 30.8 | -- | 29.9 | -- | 30.4 |
| MENTAL HEALTH TREATMENT | -- | 28.5 | -- | 28.6 | -- | 28.4 | -- | 28.5 |
| Inpatient | -- | 2.8 | -- | 2.7 | -- | 2.7 | -- | 3.1 |
| Hospital | -- | 2.2 | -- | 2.0 | -- | 2.1 | -- | 2.6 |
| Residential Mental Health Treatment Center | -- | 1.6 | -- | 1.5 | -- | 1.8 | -- | 1.5 |
| Residential Drug or Alcohol Rehab or Treatment Center | -- | 0.5 | -- | 0.5 | -- | 0.8 | -- | 0.2 |
| Some Other Place as an Inpatient | -- | 0.7 | -- | 0.9 | -- | 0.6 | -- | 0.6 |
| Outpatient | -- | 21.3 | -- | 21.5 | -- | 20.9 | -- | 21.5 |
| Mental Health Treatment Center | -- | 3.2 | -- | 2.7 | -- | 3.5 | -- | 3.2 |
| Drug or Alcohol Rehab or Treatment Center | -- | 0.4 | -- | 0.2 | -- | 0.5 | -- | 0.4 |
| Office of a Therapist, Psychologist, Psychiatrist, or Mental Health Professional | -- | 13.5 | -- | 11.8 | -- | 13.3 | -- | 15.3 |
| General Medical Clinic or Doctor’s Office | -- | 6.9 | -- | 5.3 | -- | 7.4 | -- | 7.7 |
| Hospital | -- | 1.8 | -- | 1.2 | -- | 2.0 | -- | 2.0 |
| School’s Health or Counseling Center | -- | 11.3 | -- | 13.5 | -- | 11.1 | -- | 9.7 |
| Some Other Place as an Outpatient | -- | 1.0 | -- | 0.9 | -- | 1.3 | -- | 0.8 |
| Outpatient, Other Than General Medical Clinic or Doctor’s Office | -- | 19.9 | -- | 20.3 | -- | 19.3 | -- | 20.1 |
| Prescription Medication | 13.9 | 12.9 | 12.0 | 10.9 | 14.2 | 13.2 | 15.3 | 14.4 |
| Telehealth Treatment2 | 14.2 | 13.1 | 10.7 | 11.6 | 15.5a | 13.1 | 16.1 | 14.3 |
| Prison, Jail, or Juvenile Detention Center | 1.2 | 1.2 | 1.3 | 1.2 | 1.2 | 1.4 | 1.2 | 1.0 |
| OTHER SERVICES | ||||||||
| Support Services | ||||||||
| Support Group | 7.4 | 6.7 | 7.1 | 8.5 | 8.5b | 5.9 | 6.6 | 5.9 |
| Peer Support Specialist or Recovery Coach | 3.2 | 3.1 | 2.3 | 3.2 | 3.6 | 2.9 | 3.5 | 3.1 |
| Emergency Room/Department | 2.7 | 2.6 | 2.6 | 2.6 | 3.1 | 2.3 | 2.4 | 3.0 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple types/locations for receiving mental health treatment or other services; thus, these response categories are not mutually exclusive. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Other services include treatment for mental health, emotions, or behavior through support group services; peer support specialist or recovery coach services; or treatment received in an emergency room/department. 2 Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Mental Health Treatment (2023) |
Mental Health Treatment (2024) |
Inpatient (2023) |
Inpatient (2024) |
Outpatient (2023) |
Outpatient (2024) |
Prescription Medication (2023) |
Prescription Medication (2024) |
Telehealth Treatment1 (2023) |
Telehealth Treatment1 (2024) |
Prison, Jail, or Juvenile Detention Center (2023) |
Prison, Jail, or Juvenile Detention Center (2024) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 7,393 | -- | 736 | -- | 5,525 | 3,604 | 3,343 | 3,677 | 3,389 | 314 | 312 |
| AGE GROUP | ||||||||||||
| 12-13 | -- | 2,312 | -- | 220 | -- | 1,741 | 955 | 883 | 848 | 941 | 104 | 97 |
| 14-15 | -- | 2,520 | -- | 238 | -- | 1,849 | 1,293 | 1,167 | 1,410a | 1,164 | 106 | 121 |
| 16-17 | -- | 2,561 | -- | 279 | -- | 1,936 | 1,355 | 1,293 | 1,419 | 1,283 | 103 | 93 |
| SEX | ||||||||||||
| Male | -- | 2,943 | -- | 301 | -- | 1,926 | 1,443 | 1,359 | 1,302 | 1,169 | 129 | 149 |
| Female | -- | 4,450 | -- | 435 | -- | 3,600 | 2,161 | 1,984 | 2,375 | 2,220 | 184 | 163 |
| HISPANIC ORIGIN AND RACE | ||||||||||||
| Not Hispanic or Latino | -- | 5,718 | -- | 518 | -- | 4,241 | 2,926 | 2,815 | 2,861 | 2,661 | 227 | 248 |
| AIAN | -- | 57 | -- | 12 | -- | 30 | 37 | 28 | 34 | 19 | 3 | 9 |
| Asian | -- | 242 | -- | 27 | -- | 211 | 48 | 52 | 128 | 98 | 3 | 1 |
| Black or African American | -- | 736 | -- | 116 | -- | 516 | 243 | 262 | 250 | 236 | 52 | 57 |
| NHPI | -- | * | -- | * | -- | * | * | 2 | * | 1 | * | * |
| White | -- | 4,291 | -- | 318 | -- | 3,170 | 2,407 | 2,313 | 2,284 | 2,116 | 156 | 156 |
| Two or More Races | -- | 375 | -- | 42 | -- | 301 | 186 | 157 | 160 | 191 | 13 | 24 |
| Hispanic or Latino | -- | 1,675 | -- | 218 | -- | 1,285 | 678a | 529 | 816 | 727 | 87 | 64 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple types/locations for receiving mental health treatment; thus, these response categories are not mutually exclusive. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||||
| Demographic Characteristic | Mental Health Treatment (2023) |
Mental Health Treatment (2024) |
Inpatient (2023) |
Inpatient (2024) |
Outpatient (2023) |
Outpatient (2024) |
Prescription Medication (2023) |
Prescription Medication (2024) |
Telehealth Treatment1 (2023) |
Telehealth Treatment1 (2024) |
Prison, Jail, or Juvenile Detention Center (2023) |
Prison, Jail, or Juvenile Detention Center (2024) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 28.5 | -- | 2.8 | -- | 21.3 | 13.9 | 12.9 | 14.2 | 13.1 | 1.2 | 1.2 |
| AGE GROUP | ||||||||||||
| 12-13 | -- | 28.6 | -- | 2.7 | -- | 21.5 | 12.0 | 10.9 | 10.7 | 11.6 | 1.3 | 1.2 |
| 14-15 | -- | 28.4 | -- | 2.7 | -- | 20.9 | 14.2 | 13.2 | 15.5a | 13.1 | 1.2 | 1.4 |
| 16-17 | -- | 28.5 | -- | 3.1 | -- | 21.5 | 15.3 | 14.4 | 16.1 | 14.3 | 1.2 | 1.0 |
| SEX | ||||||||||||
| Male | -- | 22.2 | -- | 2.3 | -- | 14.5 | 10.9 | 10.2 | 9.8 | 8.8 | 1.0 | 1.1 |
| Female | -- | 35.1 | -- | 3.4 | -- | 28.4 | 17.1 | 15.7 | 18.8 | 17.5 | 1.5 | 1.3 |
| HISPANIC ORIGIN AND RACE | ||||||||||||
| Not Hispanic or Latino | -- | 30.0 | -- | 2.7 | -- | 22.3 | 15.3 | 14.8 | 15.0 | 14.0 | 1.2 | 1.3 |
| AIAN | -- | 27.2 | -- | 5.9 | -- | 14.2 | 15.6 | 13.5 | 14.7 | 9.2 | 1.1 | 4.3 |
| Asian | -- | 16.0 | -- | 1.8 | -- | 13.9 | 3.3 | 3.5 | 8.8 | 6.4 | 0.2 | 0.1 |
| Black or African American | -- | 20.6 | -- | 3.3 | -- | 14.4 | 6.8 | 7.4 | 6.9 | 6.6 | 1.4 | 1.6 |
| NHPI | -- | * | -- | * | -- | * | * | 2.4 | * | 1.0 | * | * |
| White | -- | 34.0 | -- | 2.5 | -- | 25.1 | 18.8 | 18.3 | 17.8 | 16.8 | 1.2 | 1.2 |
| Two or More Races | -- | 36.0 | -- | 4.0 | -- | 28.8 | 20.1 | 15.0 | 17.3 | 18.4 | 1.4 | 2.3 |
| Hispanic or Latino | -- | 24.3 | -- | 3.2 | -- | 18.6 | 10.0a | 7.7 | 12.0 | 10.5 | 1.3 | 0.9 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple types/locations for receiving mental health treatment; thus, these response categories are not mutually exclusive. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||||
| Geographic/Socioeconomic Characteristic | Mental Health Treatment (2023) |
Mental Health Treatment (2024) |
Inpatient (2023) |
Inpatient (2024) |
Outpatient (2023) |
Outpatient (2024) |
Prescription Medication (2023) |
Prescription Medication (2024) |
Telehealth Treatment1 (2023) |
Telehealth Treatment1 (2024) |
Prison, Jail, or Juvenile Detention Center (2023) |
Prison, Jail, or Juvenile Detention Center (2024) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 7,393 | -- | 736 | -- | 5,525 | 3,604 | 3,343 | 3,677 | 3,389 | 314 | 312 |
| GEOGRAPHIC REGION | ||||||||||||
| Northeast | -- | 1,303 | -- | 121 | -- | 989 | 555 | 573 | 644 | 714 | 63 | 56 |
| Midwest | -- | 1,673 | -- | 118 | -- | 1,241 | 947 | 839 | 854 | 724 | 92a | 43 |
| South | -- | 2,738 | -- | 327 | -- | 1,990 | 1,424 | 1,295 | 1,323 | 1,134 | 120 | 153 |
| West | -- | 1,678 | -- | 171 | -- | 1,305 | 679 | 637 | 857 | 816 | 39 | 60 |
| COUNTY TYPE | ||||||||||||
| Large Metro | -- | 4,100 | -- | 349 | -- | 3,120 | 1,855 | 1,698 | 2,212 | 1,973 | 151 | 128 |
| Small Metro | -- | 2,491 | -- | 269 | -- | 1,840 | 1,228 | 1,223 | 1,073 | 1,054 | 107 | 153 |
| Nonmetro | -- | 802 | -- | 118 | -- | 565 | 521 | 423 | 391 | 362 | 56 | 31 |
| Urbanized | -- | 299 | -- | 38 | -- | 203 | 193 | 150 | 143 | 140 | 22 | 16 |
| Less Urbanized | -- | 462 | -- | 76 | -- | 329 | 282 | 248 | 205 | 199 | 31 | 14 |
| Completely Rural | -- | 41 | -- | 4 | -- | 33 | * | 25 | 44 | 24 | 3 | <1 |
| POVERTY LEVEL | ||||||||||||
| Less Than 100% | -- | 1,534 | -- | 263 | -- | 1,119 | 586 | 666 | 584 | 606 | 73 | 122 |
| 100-199% | -- | 1,366 | -- | 170 | -- | 1,026 | 668 | 557 | 639 | 612 | 67 | 59 |
| 200% or More | -- | 4,493 | -- | 303 | -- | 3,381 | 2,350 | 2,120 | 2,453 | 2,171 | 174 | 131 |
| HEALTH INSURANCE2 | ||||||||||||
| Private | -- | 4,361 | -- | 262 | -- | 3,353 | 2,170 | 2,020 | 2,291 | 2,117 | 162 | 107 |
| Medicaid/CHIP | -- | 2,997 | -- | 466 | -- | 2,180 | 1,475 | 1,366 | 1,335 | 1,279 | 182 | 204 |
| Other3 | -- | 378 | -- | 50 | -- | 251 | 189 | 176 | 220 | 157 | 4 | 19 |
| No Coverage | -- | 206 | -- | 31 | -- | 159 | 86 | 70 | 115 | 94 | 12 | 15 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple types/locations for receiving mental health treatment; thus, these response categories are not mutually exclusive. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received. 2 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 3 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||||
| Geographic/Socioeconomic Characteristic | Mental Health Treatment (2023) |
Mental Health Treatment (2024) |
Inpatient (2023) |
Inpatient (2024) |
Outpatient (2023) |
Outpatient (2024) |
Prescription Medication (2023) |
Prescription Medication (2024) |
Telehealth Treatment1 (2023) |
Telehealth Treatment1 (2024) |
Prison, Jail, or Juvenile Detention Center (2023) |
Prison, Jail, or Juvenile Detention Center (2024) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 28.5 | -- | 2.8 | -- | 21.3 | 13.9 | 12.9 | 14.2 | 13.1 | 1.2 | 1.2 |
| GEOGRAPHIC REGION | ||||||||||||
| Northeast | -- | 31.9 | -- | 3.0 | -- | 24.3 | 13.6 | 14.0 | 15.8 | 17.5 | 1.5 | 1.4 |
| Midwest | -- | 30.9 | -- | 2.2 | -- | 22.9 | 17.4 | 15.5 | 15.7 | 13.4 | 1.7a | 0.8 |
| South | -- | 26.5 | -- | 3.2 | -- | 19.3 | 13.9 | 12.5 | 12.9a | 11.0 | 1.2 | 1.5 |
| West | -- | 27.3 | -- | 2.8 | -- | 21.3 | 11.0 | 10.4 | 13.9 | 13.3 | 0.6 | 1.0 |
| COUNTY TYPE | ||||||||||||
| Large Metro | -- | 27.9 | -- | 2.4 | -- | 21.2 | 13.0 | 11.6 | 15.5a | 13.4 | 1.1 | 0.9 |
| Small Metro | -- | 29.8 | -- | 3.2 | -- | 22.0 | 14.8 | 14.6 | 13.0 | 12.6 | 1.3 | 1.8 |
| Nonmetro | -- | 27.7 | -- | 4.1 | -- | 19.5 | 15.4 | 14.6 | 11.5 | 12.5 | 1.6 | 1.1 |
| Urbanized | -- | 26.3 | -- | 3.3 | -- | 17.8 | 15.8 | 13.2 | 11.7 | 12.3 | 1.8 | 1.4 |
| Less Urbanized | -- | 30.3 | -- | 5.0 | -- | 21.6 | 15.1 | 16.3 | 11.0 | 13.1 | 1.7 | 1.0 |
| Completely Rural | -- | 17.3 | -- | 1.5 | -- | 14.1 | * | 10.5 | 14.3 | 10.1 | 0.9 | <0.1 |
| POVERTY LEVEL | ||||||||||||
| Less Than 100% | -- | 27.8 | -- | 4.8 | -- | 20.3 | 10.3 | 12.1 | 10.2 | 11.0 | 1.3 | 2.2 |
| 100-199% | -- | 25.7 | -- | 3.2 | -- | 19.3 | 12.5 | 10.5 | 11.9 | 11.5 | 1.3 | 1.1 |
| 200% or More | -- | 29.7 | -- | 2.0 | -- | 22.4 | 15.8a | 14.0 | 16.5a | 14.4 | 1.2 | 0.9 |
| HEALTH INSURANCE2 | ||||||||||||
| Private | -- | 29.8 | -- | 1.8 | -- | 22.9 | 15.5 | 13.8 | 16.4a | 14.5 | 1.2 | 0.7 |
| Medicaid/CHIP | -- | 28.7 | -- | 4.5 | -- | 20.9 | 13.5 | 13.1 | 12.2 | 12.2 | 1.7 | 2.0 |
| Other3 | -- | 27.4 | -- | 3.6 | -- | 18.1 | 13.5 | 12.7 | 15.8 | 11.4 | 0.3 | 1.4 |
| No Coverage | -- | 17.0 | -- | 2.5 | -- | 13.1 | 6.9 | 5.8 | 9.2 | 7.7 | 0.9 | 1.3 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple types/locations for receiving mental health treatment; thus, these response categories are not mutually exclusive. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received. 2 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 3 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||||
| Demographic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 7,393 | -- | 2,327 | -- | 1,775 | -- | 4,671 |
| AGE GROUP | ||||||||
| 12-13 | -- | 2,312 | -- | 466 | -- | 351 | -- | 1,627 |
| 14-15 | -- | 2,520 | -- | 841 | -- | 646 | -- | 1,562 |
| 16-17 | -- | 2,561 | -- | 1,019 | -- | 778 | -- | 1,482 |
| SEX | ||||||||
| Male | -- | 2,943 | -- | 552 | -- | 383 | -- | 2,238 |
| Female | -- | 4,450 | -- | 1,774 | -- | 1,392 | -- | 2,433 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 5,718 | -- | 1,786 | -- | 1,343 | -- | 3,654 |
| AIAN | -- | 57 | -- | * | -- | * | -- | 39 |
| Asian | -- | 242 | -- | * | -- | * | -- | 153 |
| Black or African American | -- | 736 | -- | 163 | -- | 121 | -- | 532 |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 4,291 | -- | 1,385 | -- | 1,033 | -- | 2,697 |
| Two or More Races | -- | 375 | -- | 143 | -- | 108 | -- | 215 |
| Hispanic or Latino | -- | 1,675 | -- | 540 | -- | 431 | -- | 1,017 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 28.5 | -- | 60.6 | -- | 62.6 | -- | 22.1 |
| AGE GROUP | ||||||||
| 12-13 | -- | 28.6 | -- | 60.7 | -- | 61.8 | -- | 23.7 |
| 14-15 | -- | 28.4 | -- | 61.6 | -- | 64.6 | -- | 21.8 |
| 16-17 | -- | 28.5 | -- | 59.7 | -- | 61.4 | -- | 20.8 |
| SEX | ||||||||
| Male | -- | 22.2 | -- | 51.1 | -- | 52.1 | -- | 19.1 |
| Female | -- | 35.1 | -- | 64.3 | -- | 66.3 | -- | 25.8 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 30.0 | -- | 63.3 | -- | 65.4 | -- | 23.5 |
| AIAN | -- | 27.2 | -- | * | -- | * | -- | 21.4 |
| Asian | -- | 16.0 | -- | * | -- | * | -- | 12.0 |
| Black or African American | -- | 20.6 | -- | 44.7 | -- | 46.4 | -- | 17.2 |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 34.0 | -- | 67.7 | -- | 69.7 | -- | 26.5 |
| Two or More Races | -- | 36.0 | -- | 64.5 | -- | 65.8 | -- | 27.7 |
| Hispanic or Latino | -- | 24.3 | -- | 53.2 | -- | 55.4 | -- | 18.2 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 7,393 | -- | 2,327 | -- | 1,775 | -- | 4,671 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | 1,303 | -- | 394 | -- | 327 | -- | 849 |
| Midwest | -- | 1,673 | -- | 513 | -- | 385 | -- | 1,074 |
| South | -- | 2,738 | -- | 813 | -- | 608 | -- | 1,792 |
| West | -- | 1,678 | -- | 606 | -- | 455 | -- | 956 |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 4,100 | -- | 1,198 | -- | 917 | -- | 2,662 |
| Small Metro | -- | 2,491 | -- | 866 | -- | 660 | -- | 1,511 |
| Nonmetro | -- | 802 | -- | 263 | -- | 198 | -- | 498 |
| Urbanized | -- | 299 | -- | * | -- | * | -- | 185 |
| Less Urbanized | -- | 462 | -- | 146 | -- | * | -- | 285 |
| Completely Rural | -- | 41 | -- | * | -- | * | -- | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 1,534 | -- | 450 | -- | 350 | -- | 997 |
| 100-199% | -- | 1,366 | -- | 420 | -- | 338 | -- | 863 |
| 200% or More | -- | 4,493 | -- | 1,457 | -- | 1,087 | -- | 2,812 |
| HEALTH INSURANCE6 | ||||||||
| Private | -- | 4,361 | -- | 1,360 | -- | 1,031 | -- | 2,784 |
| Medicaid/CHIP | -- | 2,997 | -- | 978 | -- | 778 | -- | 1,838 |
| Other7 | -- | 378 | -- | * | -- | * | -- | 279 |
| No Coverage | -- | 206 | -- | * | -- | * | -- | 125 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 7 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 28.5 | -- | 60.6 | -- | 62.6 | -- | 22.1 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | 31.9 | -- | 70.0 | -- | 72.8 | -- | 25.4 |
| Midwest | -- | 30.9 | -- | 62.6 | -- | 66.5 | -- | 24.5 |
| South | -- | 26.5 | -- | 54.9 | -- | 54.9 | -- | 21.0 |
| West | -- | 27.3 | -- | 62.1 | -- | 65.2 | -- | 19.5 |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 27.9 | -- | 60.8 | -- | 62.1 | -- | 22.0 |
| Small Metro | -- | 29.8 | -- | 61.8 | -- | 64.7 | -- | 22.5 |
| Nonmetro | -- | 27.7 | -- | 55.9 | -- | 58.4 | -- | 21.2 |
| Urbanized | -- | 26.3 | -- | * | -- | * | -- | 19.9 |
| Less Urbanized | -- | 30.3 | -- | 61.2 | -- | * | -- | 23.1 |
| Completely Rural | -- | 17.3 | -- | * | -- | * | -- | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 27.8 | -- | 58.8 | -- | 61.8 | -- | 21.9 |
| 100-199% | -- | 25.7 | -- | 54.8 | -- | 55.6 | -- | 19.9 |
| 200% or More | -- | 29.7 | -- | 63.1 | -- | 65.5 | -- | 22.9 |
| HEALTH INSURANCE6 | ||||||||
| Private | -- | 29.8 | -- | 61.3 | -- | 63.1 | -- | 23.4 |
| Medicaid/CHIP | -- | 28.7 | -- | 61.9 | -- | 64.5 | -- | 21.7 |
| Other7 | -- | 27.4 | -- | * | -- | * | -- | 23.6 |
| No Coverage | -- | 17.0 | -- | * | -- | * | -- | 12.5 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 7 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 736 | -- | 274 | -- | 228 | -- | 397 |
| AGE GROUP | ||||||||
| 12-13 | -- | 220 | -- | 58 | -- | 50 | -- | 128 |
| 14-15 | -- | 238 | -- | 93 | -- | 80 | -- | 133 |
| 16-17 | -- | 279 | -- | 123 | -- | 99 | -- | 136 |
| SEX | ||||||||
| Male | -- | 301 | -- | 77 | -- | 50 | -- | 205 |
| Female | -- | 435 | -- | 197 | -- | 179 | -- | 192 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 518 | -- | 201 | -- | 157 | -- | 266 |
| AIAN | -- | 12 | -- | * | -- | * | -- | 9 |
| Asian | -- | 27 | -- | * | -- | * | -- | 20 |
| Black or African American | -- | 116 | -- | 17 | -- | 14 | -- | 90 |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 318 | -- | 156 | -- | 117 | -- | 132 |
| Two or More Races | -- | 42 | -- | 19 | -- | 19 | -- | 13 |
| Hispanic or Latino | -- | 218 | -- | 73 | -- | 71 | -- | 131 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 2.8 | -- | 7.1 | -- | 8.0 | -- | 1.9 |
| AGE GROUP | ||||||||
| 12-13 | -- | 2.7 | -- | 7.6 | -- | 8.8 | -- | 1.9 |
| 14-15 | -- | 2.7 | -- | 6.8 | -- | 8.0 | -- | 1.9 |
| 16-17 | -- | 3.1 | -- | 7.2 | -- | 7.8 | -- | 1.9 |
| SEX | ||||||||
| Male | -- | 2.3 | -- | 7.1 | -- | 6.7 | -- | 1.7 |
| Female | -- | 3.4 | -- | 7.1 | -- | 8.5 | -- | 2.0 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 2.7 | -- | 7.1 | -- | 7.7 | -- | 1.7 |
| AIAN | -- | 5.9 | -- | * | -- | * | -- | 4.9 |
| Asian | -- | 1.8 | -- | * | -- | * | -- | 1.5 |
| Black or African American | -- | 3.3 | -- | 4.7 | -- | 5.5 | -- | 2.9 |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 2.5 | -- | 7.6 | -- | 7.9 | -- | 1.3 |
| Two or More Races | -- | 4.0 | -- | 8.4 | -- | 11.4 | -- | 1.6 |
| Hispanic or Latino | -- | 3.2 | -- | 7.2 | -- | 9.1 | -- | 2.3 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 736 | -- | 274 | -- | 228 | -- | 397 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | 121 | -- | 35 | -- | 35 | -- | 78 |
| Midwest | -- | 118 | -- | 44 | -- | 32 | -- | 61 |
| South | -- | 327 | -- | 111 | -- | 91 | -- | 181 |
| West | -- | 171 | -- | 83 | -- | 71 | -- | 76 |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 349 | -- | 139 | -- | 112 | -- | 179 |
| Small Metro | -- | 269 | -- | 87 | -- | 80 | -- | 165 |
| Nonmetro | -- | 118 | -- | 48 | -- | 36 | -- | 53 |
| Urbanized | -- | 38 | -- | * | -- | 7 | -- | 22 |
| Less Urbanized | -- | 76 | -- | 29 | -- | * | -- | 30 |
| Completely Rural | -- | 4 | -- | * | -- | * | -- | 1 |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 263 | -- | 67 | -- | 52 | -- | 180 |
| 100-199% | -- | 170 | -- | 75 | -- | 73 | -- | 79 |
| 200% or More | -- | 303 | -- | 132 | -- | 103 | -- | 138 |
| HEALTH INSURANCE6 | ||||||||
| Private | -- | 262 | -- | 113 | -- | 98 | -- | 120 |
| Medicaid/CHIP | -- | 466 | -- | 162 | -- | 137 | -- | 261 |
| Other7 | -- | 50 | -- | * | -- | 1 | -- | 39 |
| No Coverage | -- | 31 | -- | * | -- | * | -- | 16 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 7 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 2.8 | -- | 7.1 | -- | 8.0 | -- | 1.9 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | 3.0 | -- | 6.3 | -- | 7.8 | -- | 2.3 |
| Midwest | -- | 2.2 | -- | 5.4 | -- | 5.5 | -- | 1.4 |
| South | -- | 3.2 | -- | 7.5 | -- | 8.2 | -- | 2.1 |
| West | -- | 2.8 | -- | 8.5 | -- | 10.1 | -- | 1.5 |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 2.4 | -- | 7.0 | -- | 7.6 | -- | 1.5 |
| Small Metro | -- | 3.2 | -- | 6.2 | -- | 7.9 | -- | 2.5 |
| Nonmetro | -- | 4.1 | -- | 10.2 | -- | 10.5 | -- | 2.2 |
| Urbanized | -- | 3.3 | -- | * | -- | 4.9 | -- | 2.4 |
| Less Urbanized | -- | 5.0 | -- | 12.3 | -- | * | -- | 2.4 |
| Completely Rural | -- | 1.5 | -- | * | -- | * | -- | 0.3 |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 4.8 | -- | 8.8 | -- | 9.2 | -- | 4.0 |
| 100-199% | -- | 3.2 | -- | 9.7 | -- | 12.0 | -- | 1.8 |
| 200% or More | -- | 2.0 | -- | 5.7 | -- | 6.2 | -- | 1.1 |
| HEALTH INSURANCE6 | ||||||||
| Private | -- | 1.8 | -- | 5.1 | -- | 6.0 | -- | 1.0 |
| Medicaid/CHIP | -- | 4.5 | -- | 10.2 | -- | 11.4 | -- | 3.1 |
| Other7 | -- | 3.6 | -- | * | -- | 1.1 | -- | 3.3 |
| No Coverage | -- | 2.5 | -- | * | -- | * | -- | 1.6 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 7 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 5,525 | -- | 1,952 | -- | 1,508 | -- | 3,275 |
| AGE GROUP | ||||||||
| 12-13 | -- | 1,741 | -- | 404 | -- | 304 | -- | 1,155 |
| 14-15 | -- | 1,849 | -- | 709 | -- | 537 | -- | 1,059 |
| 16-17 | -- | 1,936 | -- | 839 | -- | 666 | -- | 1,061 |
| SEX | ||||||||
| Male | -- | 1,926 | -- | 419 | -- | 289 | -- | 1,395 |
| Female | -- | 3,600 | -- | 1,534 | -- | 1,219 | -- | 1,880 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 4,241 | -- | 1,481 | -- | 1,129 | -- | 2,555 |
| AIAN | -- | 30 | -- | * | -- | * | -- | 20 |
| Asian | -- | 211 | -- | * | -- | * | -- | 129 |
| Black or African American | -- | 516 | -- | 138 | -- | 99 | -- | 344 |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 3,170 | -- | 1,148 | -- | 870 | -- | 1,870 |
| Two or More Races | -- | 301 | -- | 112 | -- | * | -- | 178 |
| Hispanic or Latino | -- | 1,285 | -- | 471 | -- | 379 | -- | 721 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 21.3 | -- | 50.8 | -- | 53.2 | -- | 15.5 |
| AGE GROUP | ||||||||
| 12-13 | -- | 21.5 | -- | 52.6 | -- | 53.7 | -- | 16.9 |
| 14-15 | -- | 20.9 | -- | 51.9 | -- | 53.7 | -- | 14.8 |
| 16-17 | -- | 21.5 | -- | 49.2 | -- | 52.6 | -- | 14.9 |
| SEX | ||||||||
| Male | -- | 14.5 | -- | 38.7 | -- | 39.3 | -- | 11.9 |
| Female | -- | 28.4 | -- | 55.6 | -- | 58.1 | -- | 20.0 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 22.3 | -- | 52.5 | -- | 54.9 | -- | 16.4 |
| AIAN | -- | 14.2 | -- | * | -- | * | -- | 11.0 |
| Asian | -- | 13.9 | -- | * | -- | * | -- | 10.1 |
| Black or African American | -- | 14.4 | -- | 37.8 | -- | 38.2 | -- | 11.1 |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 25.1 | -- | 56.1 | -- | 58.7 | -- | 18.4 |
| Two or More Races | -- | 28.8 | -- | 50.5 | -- | * | -- | 22.9 |
| Hispanic or Latino | -- | 18.6 | -- | 46.4 | -- | 48.6 | -- | 12.9 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 5,525 | -- | 1,952 | -- | 1,508 | -- | 3,275 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | 989 | -- | 321 | -- | 269 | -- | 633 |
| Midwest | -- | 1,241 | -- | 423 | -- | 316 | -- | 743 |
| South | -- | 1,990 | -- | 676 | -- | 514 | -- | 1,203 |
| West | -- | 1,305 | -- | 532 | -- | 409 | -- | 696 |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 3,120 | -- | 1,023 | -- | 828 | -- | 1,923 |
| Small Metro | -- | 1,840 | -- | 714 | -- | 519 | -- | 1,034 |
| Nonmetro | -- | 565 | -- | 215 | -- | 162 | -- | 318 |
| Urbanized | -- | 203 | -- | * | -- | * | -- | 119 |
| Less Urbanized | -- | 329 | -- | 126 | -- | * | -- | 174 |
| Completely Rural | -- | 33 | -- | * | -- | * | -- | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 1,119 | -- | 392 | -- | 308 | -- | 667 |
| 100-199% | -- | 1,026 | -- | 346 | -- | 275 | -- | 614 |
| 200% or More | -- | 3,381 | -- | 1,215 | -- | 925 | -- | 1,994 |
| HEALTH INSURANCE6 | ||||||||
| Private | -- | 3,353 | -- | 1,140 | -- | 883 | -- | 2,047 |
| Medicaid/CHIP | -- | 2,180 | -- | 818 | -- | 653 | -- | 1,225 |
| Other7 | -- | 251 | -- | * | -- | * | -- | 169 |
| No Coverage | -- | 159 | -- | * | -- | * | -- | 86 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 7 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | -- | 21.3 | -- | 50.8 | -- | 53.2 | -- | 15.5 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | 24.3 | -- | 57.0 | -- | 59.9 | -- | 18.9 |
| Midwest | -- | 22.9 | -- | 51.7 | -- | 54.6 | -- | 17.0 |
| South | -- | 19.3 | -- | 45.6 | -- | 46.4 | -- | 14.1 |
| West | -- | 21.3 | -- | 54.5 | -- | 58.6 | -- | 14.2 |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 21.2 | -- | 52.0 | -- | 56.1 | -- | 15.9 |
| Small Metro | -- | 22.0 | -- | 51.0 | -- | 50.9 | -- | 15.4 |
| Nonmetro | -- | 19.5 | -- | 45.6 | -- | 47.6 | -- | 13.5 |
| Urbanized | -- | 17.8 | -- | * | -- | * | -- | 12.7 |
| Less Urbanized | -- | 21.6 | -- | 52.9 | -- | * | -- | 14.1 |
| Completely Rural | -- | 14.1 | -- | * | -- | * | -- | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 20.3 | -- | 51.2 | -- | 54.3 | -- | 14.7 |
| 100-199% | -- | 19.3 | -- | 45.0 | -- | 45.3 | -- | 14.2 |
| 200% or More | -- | 22.4 | -- | 52.6 | -- | 55.7 | -- | 16.2 |
| HEALTH INSURANCE6 | ||||||||
| Private | -- | 22.9 | -- | 51.4 | -- | 54.0 | -- | 17.2 |
| Medicaid/CHIP | -- | 20.9 | -- | 51.7 | -- | 54.1 | -- | 14.5 |
| Other7 | -- | 18.1 | -- | * | -- | * | -- | 14.3 |
| No Coverage | -- | 13.1 | -- | * | -- | * | -- | 8.6 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 7 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | 3,604 | 3,343 | 1,454a | 1,197 | 1,213b | 914 | 2,042 | 1,958 |
| AGE GROUP | ||||||||
| 12-13 | 955 | 883 | 225 | 155 | 175 | 119 | 685 | 658 |
| 14-15 | 1,293 | 1,167 | 522 | 476 | 448 | 369 | 730 | 617 |
| 16-17 | 1,355 | 1,293 | 708 | 566 | 590a | 426 | 627 | 683 |
| SEX | ||||||||
| Male | 1,443 | 1,359 | 317 | 292 | 249 | 186 | 1,075 | 1,002 |
| Female | 2,161 | 1,984 | 1,138a | 905 | 965b | 728 | 967 | 955 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | 2,926 | 2,815 | 1,178 | 997 | 960a | 740 | 1,653 | 1,662 |
| AIAN | 37 | 28 | * | * | * | * | 28 | 19 |
| Asian | 48 | 52 | * | * | * | * | 23 | 11 |
| Black or African American | 243 | 262 | 82 | 58 | 66 | 43 | 144 | 196 |
| NHPI | * | 2 | * | * | * | * | * | 2 |
| White | 2,407 | 2,313 | 986 | 826 | 801a | 611 | 1,348 | 1,356 |
| Two or More Races | 186 | 157 | 74 | 67 | 65 | 49 | 109 | 79 |
| Hispanic or Latino | 678a | 529 | 276 | 199 | 253 | 174 | 389 | 295 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | 13.9 | 12.9 | 32.2 | 31.2 | 36.1 | 32.2 | 10.0 | 9.3 |
| AGE GROUP | ||||||||
| 12-13 | 12.0 | 10.9 | 25.1 | 20.2 | 28.4 | 20.9 | 10.3 | 9.6 |
| 14-15 | 14.2 | 13.2 | 31.0 | 34.9 | 34.8 | 37.0 | 10.2 | 8.6 |
| 16-17 | 15.3 | 14.4 | 36.5 | 33.1 | 40.6 | 33.6 | 9.5 | 9.6 |
| SEX | ||||||||
| Male | 10.9 | 10.2 | 26.2 | 27.0 | 29.4 | 25.3 | 9.3 | 8.5 |
| Female | 17.1 | 15.7 | 34.4 | 32.8 | 38.4 | 34.7 | 11.0 | 10.1 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | 15.3 | 14.8 | 35.2 | 35.3 | 38.6 | 36.0 | 11.0 | 10.7 |
| AIAN | 15.6 | 13.5 | * | * | * | * | 15.1 | 10.4 |
| Asian | 3.3 | 3.5 | * | * | * | * | 1.9 | 0.9 |
| Black or African American | 6.8 | 7.4 | 17.8 | 16.0 | 19.2 | 16.5 | 4.8 | 6.3 |
| NHPI | * | 2.4 | * | * | * | * | * | 2.1 |
| White | 18.8 | 18.3 | 40.6 | 40.3 | 43.9 | 41.2 | 13.6 | 13.3 |
| Two or More Races | 20.1 | 15.0 | 34.1 | 30.0 | 37.3 | 29.9 | 16.2a | 10.2 |
| Hispanic or Latino | 10.0a | 7.7 | 23.6 | 19.6 | 29.2 | 22.4 | 7.3 | 5.3 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | 3,604 | 3,343 | 1,454a | 1,197 | 1,213b | 914 | 2,042 | 1,958 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | 555 | 573 | 163 | 184 | 137 | 139 | 362 | 353 |
| Midwest | 947 | 839 | 410b | 259 | 334b | 199 | 521 | 531 |
| South | 1,424 | 1,295 | 572 | 457 | 487a | 336 | 807 | 783 |
| West | 679 | 637 | 309 | 298 | 255 | 240 | 352 | 291 |
| COUNTY TYPE | ||||||||
| Large Metro | 1,855 | 1,698 | 746 | 575 | 642b | 425 | 1,053 | 1,028 |
| Small Metro | 1,228 | 1,223 | 495 | 472 | 402 | 375 | 691 | 682 |
| Nonmetro | 521 | 423 | 214a | 150 | 169 | 114 | 298 | 247 |
| Urbanized | 193 | 150 | 85 | 60 | 72 | * | 103 | 85 |
| Less Urbanized | 282 | 248 | 107 | 84 | 82 | * | 174 | 144 |
| Completely Rural | * | 25 | * | * | * | * | * | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | 586 | 666 | 223 | 183 | 190 | 145 | 333a | 437 |
| 100-199% | 668 | 557 | 279 | 196 | 242 | 169 | 376 | 321 |
| 200% or More | 2,350 | 2,120 | 952 | 818 | 782a | 599 | 1,333 | 1,199 |
| HEALTH INSURANCE6 | ||||||||
| Private | 2,170 | 2,020 | 897 | 747 | 744a | 566 | 1,218 | 1,177 |
| Medicaid/CHIP | 1,475 | 1,366 | 595 | 479 | 510a | 384 | 824 | 783 |
| Other7 | 189 | 176 | 91 | * | * | 29 | 97 | 117 |
| No Coverage | 86 | 70 | 18 | * | * | * | 65 | 44 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 7 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | 13.9 | 12.9 | 32.2 | 31.2 | 36.1 | 32.2 | 10.0 | 9.3 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | 13.6 | 14.0 | 26.2 | 32.6 | 28.4 | 31.0 | 11.0 | 10.6 |
| Midwest | 17.4 | 15.5 | 38.6 | 31.6 | 42.2 | 34.4 | 12.5 | 12.1 |
| South | 13.9 | 12.5 | 32.3 | 30.8 | 36.8 | 30.3 | 10.0 | 9.2 |
| West | 11.0 | 10.4 | 29.1 | 30.5 | 33.6 | 34.3 | 7.2 | 5.9 |
| COUNTY TYPE | ||||||||
| Large Metro | 13.0 | 11.6 | 28.6 | 29.2 | 32.9 | 28.8 | 9.5 | 8.5 |
| Small Metro | 14.8 | 14.6 | 37.6 | 33.7 | 42.3 | 36.7 | 10.4 | 10.2 |
| Nonmetro | 15.4 | 14.6 | 36.2 | 31.9 | 37.2 | 33.7 | 11.1 | 10.5 |
| Urbanized | 15.8 | 13.2 | 40.7 | 31.9 | 43.9 | * | 10.7 | 9.1 |
| Less Urbanized | 15.1 | 16.3 | 31.6 | 35.1 | 31.8 | * | 11.9 | 11.7 |
| Completely Rural | * | 10.5 | * | * | * | * | * | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | 10.3 | 12.1 | 27.5 | 23.9 | 31.0 | 25.7 | 7.2a | 9.6 |
| 100-199% | 12.5 | 10.5 | 29.1 | 25.5 | 32.6 | 27.9 | 9.0 | 7.4 |
| 200% or More | 15.8a | 14.0 | 34.7 | 35.5 | 39.0 | 36.1 | 11.5 | 9.8 |
| HEALTH INSURANCE6 | ||||||||
| Private | 15.5 | 13.8 | 35.0 | 33.7 | 39.3 | 34.7 | 11.1 | 9.9 |
| Medicaid/CHIP | 13.5 | 13.1 | 33.4 | 30.3 | 37.7 | 31.9 | 9.5 | 9.3 |
| Other7 | 13.5 | 12.7 | 29.5 | * | * | 26.4 | 9.2 | 9.9 |
| No Coverage | 6.9 | 5.8 | 10.6 | * | * | * | 6.5 | 4.4 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 7 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | 3,677 | 3,389 | 1,519a | 1,274 | 1,256b | 981 | 2,011 | 1,934 |
| AGE GROUP | ||||||||
| 12-13 | 848 | 941 | 235 | 247 | 182 | 192 | 552 | 609 |
| 14-15 | 1,410a | 1,164 | 595a | 438 | 507a | 357 | 758 | 670 |
| 16-17 | 1,419 | 1,283 | 689 | 589 | 566a | 432 | 702 | 656 |
| SEX | ||||||||
| Male | 1,302 | 1,169 | 319 | 288 | 244 | 181 | 912 | 822 |
| Female | 2,375 | 2,220 | 1,200a | 986 | 1,012a | 801 | 1,100 | 1,112 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | 2,861 | 2,661 | 1,190a | 989 | 968b | 747 | 1,559 | 1,526 |
| AIAN | 34 | 19 | * | * | * | * | 21 | 13 |
| Asian | 128 | 98 | * | * | * | * | 64 | 43 |
| Black or African American | 250 | 236 | 84 | 59 | 72a | 33 | 155 | 170 |
| NHPI | * | 1 | * | * | * | * | * | <1 |
| White | 2,284 | 2,116 | 959a | 780 | 770a | 598 | 1,242 | 1,212 |
| Two or More Races | 160 | 191 | 80 | 93 | 71 | 68 | 77 | 88 |
| Hispanic or Latino | 816 | 727 | 329 | 284 | 288 | 234 | 453 | 408 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | 14.2 | 13.1 | 33.6 | 33.2 | 37.4 | 34.6 | 9.9 | 9.1 |
| AGE GROUP | ||||||||
| 12-13 | 10.7 | 11.6 | 26.2 | 32.1 | 29.5 | 33.9 | 8.3 | 8.9 |
| 14-15 | 15.5a | 13.1 | 35.4 | 32.1 | 39.4 | 35.7 | 10.6 | 9.3 |
| 16-17 | 16.1 | 14.3 | 35.5 | 34.5 | 39.0 | 34.1 | 10.6 | 9.2 |
| SEX | ||||||||
| Male | 9.8 | 8.8 | 26.4 | 26.6 | 28.9 | 24.5 | 7.9 | 7.0 |
| Female | 18.8 | 17.5 | 36.3 | 35.7 | 40.3 | 38.2 | 12.5 | 11.8 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | 15.0 | 14.0 | 35.5 | 35.0 | 38.9 | 36.3 | 10.3 | 9.8 |
| AIAN | 14.7 | 9.2 | * | * | * | * | 11.7 | 7.0 |
| Asian | 8.8 | 6.4 | * | * | * | * | 5.3 | 3.4 |
| Black or African American | 6.9 | 6.6 | 18.3 | 16.1 | 21.1 | 12.9 | 5.2 | 5.5 |
| NHPI | * | 1.0 | * | * | * | * | * | 0.5 |
| White | 17.8 | 16.8 | 39.5 | 38.1 | 42.2 | 40.3 | 12.5 | 11.9 |
| Two or More Races | 17.3 | 18.4 | 37.0 | 41.9 | 40.9 | 41.7 | 11.4 | 11.3 |
| Hispanic or Latino | 12.0 | 10.5 | 28.2 | 28.0 | 33.2 | 30.1 | 8.5 | 7.3 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | 3,677 | 3,389 | 1,519a | 1,274 | 1,256b | 981 | 2,011 | 1,934 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | 644 | 714 | 204 | 267 | 177 | 205 | 410 | 408 |
| Midwest | 854 | 724 | 385b | 250 | 303a | 199 | 427 | 440 |
| South | 1,323 | 1,134 | 502 | 431 | 414 | 322 | 760 | 661 |
| West | 857 | 816 | 427 | 325 | 362 | 256 | 414 | 425 |
| COUNTY TYPE | ||||||||
| Large Metro | 2,212 | 1,973 | 881a | 690 | 728b | 518 | 1,226 | 1,179 |
| Small Metro | 1,073 | 1,054 | 475 | 444 | 404 | 351 | 566 | 552 |
| Nonmetro | 391 | 362 | 163 | 139 | 124 | 112 | 220 | 203 |
| Urbanized | 143 | 140 | 59 | 62 | 50 | * | 79 | 74 |
| Less Urbanized | 205 | 199 | 85 | 71 | 59 | 56 | 118 | 112 |
| Completely Rural | 44 | 24 | * | * | * | * | 23 | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | 584 | 606 | 220 | 208 | 193 | 153 | 332 | 366 |
| 100-199% | 639 | 612 | 237 | 215 | 196 | 167 | 366 | 357 |
| 200% or More | 2,453 | 2,171 | 1,062a | 850 | 867a | 661 | 1,313 | 1,212 |
| HEALTH INSURANCE6 | ||||||||
| Private | 2,291 | 2,117 | 975 | 788 | 793 | 632 | 1,241 | 1,220 |
| Medicaid/CHIP | 1,335 | 1,279 | 535 | 489 | 460 | 370 | 741 | 710 |
| Other7 | 220 | 157 | 87 | * | * | 27 | 116 | 107 |
| No Coverage | 115 | 94 | * | * | * | * | 76 | 49 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 7 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | 14.2 | 13.1 | 33.6 | 33.2 | 37.4 | 34.6 | 9.9 | 9.1 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | 15.8 | 17.5 | 32.8a | 47.4 | 36.8 | 45.6 | 12.5 | 12.2 |
| Midwest | 15.7 | 13.4 | 36.2 | 30.6 | 38.2 | 34.4 | 10.3 | 10.1 |
| South | 12.9a | 11.0 | 28.4 | 29.1 | 31.2 | 29.0 | 9.4 | 7.8 |
| West | 13.9 | 13.3 | 40.3 | 33.3 | 47.6a | 36.6 | 8.5 | 8.7 |
| COUNTY TYPE | ||||||||
| Large Metro | 15.5a | 13.4 | 33.8 | 35.0 | 37.3 | 35.1 | 11.1 | 9.7 |
| Small Metro | 13.0 | 12.6 | 36.1 | 31.7 | 42.5a | 34.5 | 8.5 | 8.2 |
| Nonmetro | 11.5 | 12.5 | 27.6 | 29.6 | 27.3 | 33.0 | 8.2 | 8.7 |
| Urbanized | 11.7 | 12.3 | 28.2 | 33.3 | 30.7 | * | 8.2 | 7.9 |
| Less Urbanized | 11.0 | 13.1 | 25.2 | 29.7 | 22.8 | 33.9 | 8.1 | 9.1 |
| Completely Rural | 14.3 | 10.1 | * | * | * | * | 8.9 | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | 10.2 | 11.0 | 27.1 | 27.2 | 31.6 | 26.9 | 7.2 | 8.0 |
| 100-199% | 11.9 | 11.5 | 24.8 | 28.1 | 26.4 | 27.6 | 8.7 | 8.2 |
| 200% or More | 16.5a | 14.4 | 38.7 | 36.8 | 43.2 | 39.8 | 11.3 | 9.9 |
| HEALTH INSURANCE6 | ||||||||
| Private | 16.4a | 14.5 | 38.0 | 35.5 | 41.9 | 38.7 | 11.3 | 10.2 |
| Medicaid/CHIP | 12.2 | 12.2 | 30.0 | 31.0 | 34.1 | 30.7 | 8.5 | 8.4 |
| Other7 | 15.8 | 11.4 | 28.1 | * | * | 24.1 | 11.1 | 9.0 |
| No Coverage | 9.2 | 7.7 | * | * | * | * | 7.6 | 4.9 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 7 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Among People Aged 12 to 17 Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 1,715 | -- | 288 | -- | 1,426 | -- | 16,546 |
| AGE GROUP | ||||||||
| 12-13 | -- | 364 | -- | 39 | -- | 326 | -- | 5,273 |
| 14-15 | -- | 571 | -- | 76 | -- | 495 | -- | 5,664 |
| 16-17 | -- | 780 | -- | 174 | -- | 606 | -- | 5,608 |
| SEX | ||||||||
| Male | -- | 489 | -- | 95 | -- | 394 | -- | 9,657 |
| Female | -- | 1,226 | -- | 193 | -- | 1,033 | -- | 6,888 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 1,285 | -- | 239 | -- | 1,047 | -- | 11,824 |
| AIAN | -- | 8 | -- | 3 | -- | 5 | -- | 143 |
| Asian | -- | 115 | -- | 32 | -- | 83 | -- | 1,138 |
| Black or African American | -- | 165 | -- | 22 | -- | 143 | -- | 2,617 |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 886 | -- | 170 | -- | 716 | -- | 7,339 |
| Two or More Races | -- | 111 | -- | 12 | -- | 98 | -- | 543 |
| Hispanic or Latino | -- | 429 | -- | 50 | -- | 380 | -- | 4,722 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Among People Aged 12 to 17 Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 9.4 | -- | 1.6 | -- | 7.8 | -- | 90.6 |
| AGE GROUP | ||||||||
| 12-13 | -- | 6.5 | -- | 0.7 | -- | 5.8 | -- | 93.5 |
| 14-15 | -- | 9.2 | -- | 1.2 | -- | 7.9 | -- | 90.8 |
| 16-17 | -- | 12.2 | -- | 2.7 | -- | 9.5 | -- | 87.8 |
| SEX | ||||||||
| Male | -- | 4.8 | -- | 0.9 | -- | 3.9 | -- | 95.2 |
| Female | -- | 15.1 | -- | 2.4 | -- | 12.7 | -- | 84.9 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 9.8 | -- | 1.8 | -- | 8.0 | -- | 90.2 |
| AIAN | -- | 5.3 | -- | 2.0 | -- | 3.3 | -- | 94.7 |
| Asian | -- | 9.2 | -- | 2.5 | -- | 6.7 | -- | 90.8 |
| Black or African American | -- | 5.9 | -- | 0.8 | -- | 5.1 | -- | 94.1 |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 10.8 | -- | 2.1 | -- | 8.7 | -- | 89.2 |
| Two or More Races | -- | 16.9 | -- | 1.8 | -- | 15.1 | -- | 83.1 |
| Hispanic or Latino | -- | 8.3 | -- | 1.0 | -- | 7.4 | -- | 91.7 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Among People Aged 12 to 17 Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 1,715 | -- | 288 | -- | 1,426 | -- | 16,546 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | 255 | -- | 52 | -- | 203 | -- | 2,454 |
| Midwest | -- | 314 | -- | 48 | -- | 266 | -- | 3,367 |
| South | -- | 750 | -- | 120 | -- | 630 | -- | 6,746 |
| West | -- | 396 | -- | 69 | -- | 327 | -- | 3,978 |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 1,005 | -- | 154 | -- | 851 | -- | 9,393 |
| Small Metro | -- | 549 | -- | 103 | -- | 446 | -- | 5,240 |
| Nonmetro | -- | 161 | -- | 31 | -- | 130 | -- | 1,913 |
| Urbanized | -- | 74 | -- | 14 | -- | 59 | -- | 758 |
| Less Urbanized | -- | 71 | -- | 15 | -- | 56 | -- | 976 |
| Completely Rural | -- | * | -- | * | -- | * | -- | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 245 | -- | 41 | -- | 204 | -- | 3,658 |
| 100-199% | -- | 332 | -- | 59 | -- | 273 | -- | 3,565 |
| 200% or More | -- | 1,138 | -- | 188 | -- | 950 | -- | 9,323 |
| HEALTH INSURANCE1 | ||||||||
| Private | -- | 1,183 | -- | 177 | -- | 1,006 | -- | 8,964 |
| Medicaid/CHIP | -- | 491 | -- | 94 | -- | 397 | -- | 6,810 |
| Other2 | -- | 77 | -- | 11 | -- | 66 | -- | 894 |
| No Coverage | -- | 70 | -- | 20 | -- | 51 | -- | 924 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. 1 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 2 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Among People Aged 12 to 17 Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 9.4 | -- | 1.6 | -- | 7.8 | -- | 90.6 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | 9.4 | -- | 1.9 | -- | 7.5 | -- | 90.6 |
| Midwest | -- | 8.5 | -- | 1.3 | -- | 7.2 | -- | 91.5 |
| South | -- | 10.0 | -- | 1.6 | -- | 8.4 | -- | 90.0 |
| West | -- | 9.1 | -- | 1.6 | -- | 7.5 | -- | 90.9 |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 9.7 | -- | 1.5 | -- | 8.2 | -- | 90.3 |
| Small Metro | -- | 9.5 | -- | 1.8 | -- | 7.7 | -- | 90.5 |
| Nonmetro | -- | 7.8 | -- | 1.5 | -- | 6.3 | -- | 92.2 |
| Urbanized | -- | 8.9 | -- | 1.7 | -- | 7.1 | -- | 91.1 |
| Less Urbanized | -- | 6.8 | -- | 1.5 | -- | 5.4 | -- | 93.2 |
| Completely Rural | -- | * | -- | * | -- | * | -- | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 6.3 | -- | 1.0 | -- | 5.2 | -- | 93.7 |
| 100-199% | -- | 8.5 | -- | 1.5 | -- | 7.0 | -- | 91.5 |
| 200% or More | -- | 10.9 | -- | 1.8 | -- | 9.1 | -- | 89.1 |
| HEALTH INSURANCE1 | ||||||||
| Private | -- | 11.7 | -- | 1.7 | -- | 9.9 | -- | 88.3 |
| Medicaid/CHIP | -- | 6.7 | -- | 1.3 | -- | 5.4 | -- | 93.3 |
| Other2 | -- | 7.9 | -- | 1.1 | -- | 6.8 | -- | 92.1 |
| No Coverage | -- | 7.1 | -- | 2.0 | -- | 5.1 | -- | 92.9 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. 1 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 2 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Among People Aged 12 to 17 with Past Year Major Depressive Episode Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 637 | -- | 123 | -- | 513 | -- | 864 |
| AGE GROUP | ||||||||
| 12-13 | -- | 123 | -- | * | -- | 108 | -- | 168 |
| 14-15 | -- | 228 | -- | 40 | -- | 187 | -- | 295 |
| 16-17 | -- | 286 | -- | 67 | -- | 218 | -- | 401 |
| SEX | ||||||||
| Male | -- | 142 | -- | 29 | -- | 113 | -- | 387 |
| Female | -- | 495 | -- | 94 | -- | 400 | -- | 478 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 460 | -- | 107 | -- | 353 | -- | 571 |
| AIAN | -- | * | -- | * | -- | * | -- | * |
| Asian | -- | * | -- | * | -- | * | -- | * |
| Black or African American | -- | 52 | -- | 7 | -- | 46 | -- | 149 |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 326 | -- | 81 | -- | 244 | -- | 330 |
| Two or More Races | -- | * | -- | * | -- | * | -- | * |
| Hispanic or Latino | -- | 177 | -- | 16 | -- | 161 | -- | 293 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Among People Aged 12 to 17 with Past Year Major Depressive Episode Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 42.4 | -- | 8.1 | -- | 34.2 | -- | 57.6 |
| AGE GROUP | ||||||||
| 12-13 | -- | 42.3 | -- | * | -- | 36.9 | -- | 57.7 |
| 14-15 | -- | 43.5 | -- | 7.7 | -- | 35.8 | -- | 56.5 |
| 16-17 | -- | 41.6 | -- | 9.8 | -- | 31.8 | -- | 58.4 |
| SEX | ||||||||
| Male | -- | 26.8 | -- | 5.5 | -- | 21.3 | -- | 73.2 |
| Female | -- | 50.9 | -- | 9.6 | -- | 41.2 | -- | 49.1 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 44.6 | -- | 10.3 | -- | 34.2 | -- | 55.4 |
| AIAN | -- | * | -- | * | -- | * | -- | * |
| Asian | -- | * | -- | * | -- | * | -- | * |
| Black or African American | -- | 26.0 | -- | 3.3 | -- | 22.8 | -- | 74.0 |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 49.6 | -- | 12.3 | -- | 37.3 | -- | 50.4 |
| Two or More Races | -- | * | -- | * | -- | * | -- | * |
| Hispanic or Latino | -- | 37.6 | -- | 3.4 | -- | 34.2 | -- | 62.4 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Among People Aged 12 to 17 with Past Year Major Depressive Episode Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 637 | -- | 123 | -- | 513 | -- | 864 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | * | -- | * | -- | * | -- | * |
| Midwest | -- | 108 | -- | 24 | -- | 84 | -- | 196 |
| South | -- | 312 | -- | 65 | -- | 247 | -- | 351 |
| West | -- | 135 | -- | 25 | -- | 110 | -- | 230 |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 358 | -- | 67 | -- | 291 | -- | 408 |
| Small Metro | -- | 199 | -- | 32 | -- | 167 | -- | 329 |
| Nonmetro | -- | 80 | -- | 24 | -- | 55 | -- | 128 |
| Urbanized | -- | * | -- | * | -- | 14 | -- | * |
| Less Urbanized | -- | * | -- | * | -- | * | -- | * |
| Completely Rural | -- | * | -- | * | -- | * | -- | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 116 | -- | 14 | -- | 102 | -- | 195 |
| 100-199% | -- | 118 | -- | 20 | -- | 97 | -- | 224 |
| 200% or More | -- | 403 | -- | 89 | -- | 314 | -- | 445 |
| HEALTH INSURANCE1 | ||||||||
| Private | -- | 411 | -- | 75 | -- | 336 | -- | 446 |
| Medicaid/CHIP | -- | 209 | -- | 34 | -- | 175 | -- | 384 |
| Other2 | -- | * | -- | * | -- | * | -- | * |
| No Coverage | -- | * | -- | * | -- | * | -- | * |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. 1 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 2 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Among People Aged 12 to 17 with Past Year Major Depressive Episode Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 42.4 | -- | 8.1 | -- | 34.2 | -- | 57.6 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | * | -- | * | -- | * | -- | * |
| Midwest | -- | 35.6 | -- | 7.8 | -- | 27.7 | -- | 64.4 |
| South | -- | 47.1 | -- | 9.8 | -- | 37.3 | -- | 52.9 |
| West | -- | 37.0 | -- | 6.8 | -- | 30.1 | -- | 63.0 |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 46.7 | -- | 8.7 | -- | 37.9 | -- | 53.3 |
| Small Metro | -- | 37.7 | -- | 5.9 | -- | 31.7 | -- | 62.3 |
| Nonmetro | -- | 38.4 | -- | 11.8 | -- | 26.6 | -- | 61.6 |
| Urbanized | -- | * | -- | * | -- | 17.4 | -- | * |
| Less Urbanized | -- | * | -- | * | -- | * | -- | * |
| Completely Rural | -- | * | -- | * | -- | * | -- | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 37.3 | -- | 4.5 | -- | 32.7 | -- | 62.7 |
| 100-199% | -- | 34.5 | -- | 5.9 | -- | 28.5 | -- | 65.5 |
| 200% or More | -- | 47.5 | -- | 10.4 | -- | 37.0 | -- | 52.5 |
| HEALTH INSURANCE1 | ||||||||
| Private | -- | 48.0 | -- | 8.7 | -- | 39.2 | -- | 52.0 |
| Medicaid/CHIP | -- | 35.2 | -- | 5.6 | -- | 29.5 | -- | 64.8 |
| Other2 | -- | * | -- | * | -- | * | -- | * |
| No Coverage | -- | * | -- | * | -- | * | -- | * |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. 1 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 2 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Among People Aged 12 to 17 with Past Year Major Depressive Episode with Severe Impairment Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 506 | -- | 113 | -- | 393 | -- | 542 |
| AGE GROUP | ||||||||
| 12-13 | -- | * | -- | * | -- | * | -- | * |
| 14-15 | -- | 175 | -- | 39 | -- | 136 | -- | 177 |
| 16-17 | -- | 236 | -- | 61 | -- | 175 | -- | 253 |
| SEX | ||||||||
| Male | -- | 98 | -- | 27 | -- | 71 | -- | 254 |
| Female | -- | 408 | -- | 86 | -- | 322 | -- | 288 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 358 | -- | 99 | -- | 260 | -- | 347 |
| AIAN | -- | * | -- | * | -- | * | -- | * |
| Asian | -- | * | -- | * | -- | * | -- | * |
| Black or African American | -- | * | -- | * | -- | * | -- | * |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 242 | -- | 74 | -- | 168 | -- | 201 |
| Two or More Races | -- | * | -- | * | -- | * | -- | * |
| Hispanic or Latino | -- | 148 | -- | 14 | -- | 134 | -- | 195 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. NOTE: Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | Among People Aged 12 to 17 with Past Year Major Depressive Episode with Severe Impairment Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 48.3 | -- | 10.7 | -- | 37.5 | -- | 51.7 |
| AGE GROUP | ||||||||
| 12-13 | -- | * | -- | * | -- | * | -- | * |
| 14-15 | -- | 49.7 | -- | 11.1 | -- | 38.5 | -- | 50.3 |
| 16-17 | -- | 48.3 | -- | 12.4 | -- | 35.9 | -- | 51.7 |
| SEX | ||||||||
| Male | -- | 27.8 | -- | 7.7 | -- | 20.1 | -- | 72.2 |
| Female | -- | 58.6 | -- | 12.1 | -- | 46.3 | -- | 41.4 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | -- | 50.8 | -- | 13.9 | -- | 36.8 | -- | 49.2 |
| AIAN | -- | * | -- | * | -- | * | -- | * |
| Asian | -- | * | -- | * | -- | * | -- | * |
| Black or African American | -- | * | -- | * | -- | * | -- | * |
| NHPI | -- | * | -- | * | -- | * | -- | * |
| White | -- | 54.5 | -- | 16.4 | -- | 37.9 | -- | 45.5 |
| Two or More Races | -- | * | -- | * | -- | * | -- | * |
| Hispanic or Latino | -- | 43.2 | -- | 4.1 | -- | 39.0 | -- | 56.8 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. NOTE: Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Among People Aged 12 to 17 with Past Year Major Depressive Episode with Severe Impairment Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 506 | -- | 113 | -- | 393 | -- | 542 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | * | -- | * | -- | * | -- | * |
| Midwest | -- | 84 | -- | 18 | -- | 66 | -- | 108 |
| South | -- | 248 | -- | 62 | -- | 186 | -- | 246 |
| West | -- | * | -- | 24 | -- | 84 | -- | * |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 286 | -- | 66 | -- | 219 | -- | 268 |
| Small Metro | -- | 159 | -- | 25 | -- | 135 | -- | 193 |
| Nonmetro | -- | 61 | -- | * | -- | * | -- | 80 |
| Urbanized | -- | * | -- | * | -- | * | -- | * |
| Less Urbanized | -- | * | -- | * | -- | * | -- | * |
| Completely Rural | -- | * | -- | * | -- | * | -- | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 105 | -- | 14 | -- | 91 | -- | 108 |
| 100-199% | -- | 98 | -- | 17 | -- | 82 | -- | 165 |
| 200% or More | -- | 302 | -- | 82 | -- | 220 | -- | 269 |
| HEALTH INSURANCE1 | ||||||||
| Private | -- | 310 | -- | 68 | -- | 243 | -- | 291 |
| Medicaid/CHIP | -- | 181 | -- | 32 | -- | 149 | -- | 238 |
| Other2 | -- | * | -- | * | -- | * | -- | * |
| No Coverage | -- | * | -- | * | -- | * | -- | * |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. NOTE: Respondents with unknown MDE data or unknown impairment data were excluded. 1 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 2 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Geographic/Socioeconomic Characteristic | Among People Aged 12 to 17 with Past Year Major Depressive Episode with Severe Impairment Who Did Not Receive Mental Health Treatment in Past Year | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
Did Not Perceive Need for Mental Health Treatment (2023) |
Did Not Perceive Need for Mental Health Treatment (2024) |
|
| TOTAL | -- | 48.3 | -- | 10.7 | -- | 37.5 | -- | 51.7 |
| GEOGRAPHIC REGION | ||||||||
| Northeast | -- | * | -- | * | -- | * | -- | * |
| Midwest | -- | 43.8 | -- | 9.2 | -- | 34.5 | -- | 56.2 |
| South | -- | 50.2 | -- | 12.4 | -- | 37.7 | -- | 49.8 |
| West | -- | * | -- | 10.0 | -- | 35.3 | -- | * |
| COUNTY TYPE | ||||||||
| Large Metro | -- | 51.6 | -- | 11.9 | -- | 39.6 | -- | 48.4 |
| Small Metro | -- | 45.3 | -- | 6.8 | -- | 38.3 | -- | 54.7 |
| Nonmetro | -- | 43.1 | -- | * | -- | * | -- | 56.9 |
| Urbanized | -- | * | -- | * | -- | * | -- | * |
| Less Urbanized | -- | * | -- | * | -- | * | -- | * |
| Completely Rural | -- | * | -- | * | -- | * | -- | * |
| POVERTY LEVEL | ||||||||
| Less Than 100% | -- | 49.4 | -- | 6.6 | -- | 42.7 | -- | 50.6 |
| 100-199% | -- | 37.4 | -- | 6.3 | -- | 30.9 | -- | 62.6 |
| 200% or More | -- | 52.9 | -- | 14.3 | -- | 38.6 | -- | 47.1 |
| HEALTH INSURANCE1 | ||||||||
| Private | -- | 51.6 | -- | 11.2 | -- | 40.4 | -- | 48.4 |
| Medicaid/CHIP | -- | 43.1 | -- | 7.4 | -- | 35.6 | -- | 56.9 |
| Other2 | -- | * | -- | * | -- | * | -- | * |
| No Coverage | -- | * | -- | * | -- | * | -- | * |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. NOTE: Respondents with unknown MDE data or unknown impairment data were excluded. 1 Respondents could indicate multiple types of health insurance; thus, these response categories are not mutually exclusive. 2 Other health insurance is defined as having Medicare, military-related health care, or any other type of health insurance. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Reason Did Not Receive Mental Health Treatment | Among People Aged 12 to 17 Who Did Not Receive Mental Health Treatment and Had a Perceived Unmet Need for Mental Health Treatment in Past Year | |||||
|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
|
| Thought It Would Cost Too Much | -- | 543 | -- | 92 | -- | 451 |
| Did Not Have Health Insurance Coverage for Mental Health Treatment | -- | 170 | -- | 33 | -- | 137 |
| Health Insurance Would Not Pay Enough of Costs for Treatment | -- | 174 | -- | 31 | -- | 143 |
| Did Not Know How or Where to Get Treatment | -- | 754 | -- | 125 | -- | 628 |
| Could Not Find Treatment Program or Healthcare Professional They Wanted to Go to | -- | 375 | -- | 83 | -- | 292 |
| No Openings in Treatment Program or with Healthcare Professional They Wanted to Go to | -- | 114 | -- | 51 | -- | 64 |
| Had Problems with Things Like Transportation, Childcare, or Getting Appointments at Times That Worked for Them | -- | 304 | -- | 71 | -- | 233 |
| Did Not Have Enough Time for Treatment | -- | 510 | -- | 111 | -- | 399 |
| Worried That Information Would Not Be Kept Private | -- | 830 | -- | 120 | -- | 710 |
| Worried about What People Would Think or Say if They Got Treatment | -- | 890 | -- | 117 | -- | 773 |
| Thought That if People Knew They Were in Treatment, Bad Things Would Happen, Like Losing Their Job, Home, or Children | -- | 196 | -- | 31 | -- | 166 |
| Not Ready to Start Treatment | -- | 694 | -- | 86 | -- | 608 |
| Thought They Should Have Been Able to Handle Their Mental Health, Emotions, or Behavior on Their Own | -- | 1,358 | -- | * | -- | 1,169 |
| Thought Their Family, Friends, or Religious Group Would Not Like It if They Got Treatment | -- | 630 | -- | 75 | -- | 555 |
| Afraid of Being Committed to Hospital or Forced into Treatment against Their Will | -- | 558 | -- | 106 | -- | 452 |
| Thought They Would Be Told They Needed to Take Medication | -- | 486 | -- | 94 | -- | 392 |
| Did Not Think Treatment Would Help Them | -- | 753 | -- | 137 | -- | 615 |
| Thought No One Would Care if They Got Better | -- | 586 | -- | 85 | -- | 502 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple reasons for not receiving mental health treatment; thus, these response categories are not mutually exclusive. Respondents with unknown reason for not receiving treatment data were excluded. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Reason Did Not Receive Mental Health Treatment | Among People Aged 12 to 17 Who Did Not Receive Mental Health Treatment and Had a Perceived Unmet Need for Mental Health Treatment in Past Year | |||||
|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
|
| Thought It Would Cost Too Much | -- | 31.8 | -- | 31.8 | -- | 31.9 |
| Did Not Have Health Insurance Coverage for Mental Health Treatment | -- | 10.6 | -- | 12.3 | -- | 10.3 |
| Health Insurance Would Not Pay Enough of Costs for Treatment | -- | 10.9 | -- | 11.2 | -- | 10.9 |
| Did Not Know How or Where to Get Treatment | -- | 44.4 | -- | 43.4 | -- | 44.6 |
| Could Not Find Treatment Program or Healthcare Professional They Wanted to Go to | -- | 22.3 | -- | 31.0 | -- | 20.6 |
| No Openings in Treatment Program or with Healthcare Professional They Wanted to Go to | -- | 6.9 | -- | 18.0 | -- | 4.6 |
| Had Problems with Things Like Transportation, Childcare, or Getting Appointments at Times That Worked for Them | -- | 17.9 | -- | 24.7 | -- | 16.5 |
| Did Not Have Enough Time for Treatment | -- | 30.2 | -- | 38.5 | -- | 28.4 |
| Worried That Information Would Not Be Kept Private | -- | 48.6 | -- | 41.8 | -- | 50.0 |
| Worried about What People Would Think or Say if They Got Treatment | -- | 52.6 | -- | 40.6 | -- | 55.1 |
| Thought That if People Knew They Were in Treatment, Bad Things Would Happen, Like Losing Their Job, Home, or Children | -- | 11.6 | -- | 10.9 | -- | 11.8 |
| Not Ready to Start Treatment | -- | 41.4 | -- | 30.6 | -- | 43.5 |
| Thought They Should Have Been Able to Handle Their Mental Health, Emotions, or Behavior on Their Own | -- | 79.9 | -- | * | -- | 82.3 |
| Thought Their Family, Friends, or Religious Group Would Not Like It if They Got Treatment | -- | 37.0 | -- | 26.1 | -- | 39.2 |
| Afraid of Being Committed to Hospital or Forced into Treatment against Their Will | -- | 32.8 | -- | 36.8 | -- | 31.9 |
| Thought They Would Be Told They Needed to Take Medication | -- | 28.8 | -- | 32.6 | -- | 28.0 |
| Did Not Think Treatment Would Help Them | -- | 44.7 | -- | 47.7 | -- | 44.0 |
| Thought No One Would Care if They Got Better | -- | 34.9 | -- | 30.2 | -- | 35.8 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple reasons for not receiving mental health treatment; thus, these response categories are not mutually exclusive. Respondents with unknown reason for not receiving treatment data were excluded. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Reason Did Not Receive Mental Health Treatment | Among People Aged 12 to 17 with Major Depressive Episode Who Did Not Receive Mental Health Treatment and Had a Perceived Unmet Need for Mental Health Treatment in Past Year | |||||
|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
|
| Thought It Would Cost Too Much | -- | 249 | -- | * | -- | 202 |
| Did Not Have Health Insurance Coverage for Mental Health Treatment | -- | 85 | -- | * | -- | 71 |
| Health Insurance Would Not Pay Enough of Costs for Treatment | -- | 89 | -- | * | -- | 68 |
| Did Not Know How or Where to Get Treatment | -- | 323 | -- | * | -- | 256 |
| Could Not Find Treatment Program or Healthcare Professional They Wanted to Go to | -- | 179 | -- | * | -- | 126 |
| No Openings in Treatment Program or with Healthcare Professional They Wanted to Go to | -- | 52 | -- | * | -- | 28 |
| Had Problems with Things Like Transportation, Childcare, or Getting Appointments at Times That Worked for Them | -- | 142 | -- | * | -- | 104 |
| Did Not Have Enough Time for Treatment | -- | 197 | -- | * | -- | 133 |
| Worried That Information Would Not Be Kept Private | -- | 412 | -- | * | -- | 340 |
| Worried about What People Would Think or Say if They Got Treatment | -- | 447 | -- | * | -- | 380 |
| Thought That if People Knew They Were in Treatment, Bad Things Would Happen, Like Losing Their Job, Home, or Children | -- | 132 | -- | * | -- | 104 |
| Not Ready to Start Treatment | -- | 287 | -- | * | -- | 225 |
| Thought They Should Have Been Able to Handle Their Mental Health, Emotions, or Behavior on Their Own | -- | 576 | -- | * | -- | 476 |
| Thought Their Family, Friends, or Religious Group Would Not Like It if They Got Treatment | -- | 313 | -- | * | -- | 270 |
| Afraid of Being Committed to Hospital or Forced into Treatment against Their Will | -- | 340 | -- | * | -- | 272 |
| Thought They Would Be Told They Needed to Take Medication | -- | 292 | -- | * | -- | 229 |
| Did Not Think Treatment Would Help Them | -- | 372 | -- | * | -- | 289 |
| Thought No One Would Care if They Got Better | -- | 360 | -- | * | -- | 288 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple reasons for not receiving mental health treatment; thus, these response categories are not mutually exclusive. Respondents with unknown reason for not receiving treatment data were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Reason Did Not Receive Mental Health Treatment | Among People Aged 12 to 17 with Major Depressive Episode Who Did Not Receive Mental Health Treatment and Had a Perceived Unmet Need for Mental Health Treatment in Past Year | |||||
|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
|
| Thought It Would Cost Too Much | -- | 39.1 | -- | * | -- | 39.3 |
| Did Not Have Health Insurance Coverage for Mental Health Treatment | -- | 14.1 | -- | * | -- | 14.5 |
| Health Insurance Would Not Pay Enough of Costs for Treatment | -- | 14.7 | -- | * | -- | 14.0 |
| Did Not Know How or Where to Get Treatment | -- | 51.2 | -- | * | -- | 50.3 |
| Could Not Find Treatment Program or Healthcare Professional They Wanted to Go to | -- | 28.6 | -- | * | -- | 24.7 |
| No Openings in Treatment Program or with Healthcare Professional They Wanted to Go to | -- | 8.3 | -- | * | -- | 5.6 |
| Had Problems with Things Like Transportation, Childcare, or Getting Appointments at Times That Worked for Them | -- | 22.6 | -- | * | -- | 20.5 |
| Did Not Have Enough Time for Treatment | -- | 31.5 | -- | * | -- | 26.4 |
| Worried That Information Would Not Be Kept Private | -- | 64.9 | -- | * | -- | 66.4 |
| Worried about What People Would Think or Say if They Got Treatment | -- | 70.5 | -- | * | -- | 74.3 |
| Thought That if People Knew They Were in Treatment, Bad Things Would Happen, Like Losing Their Job, Home, or Children | -- | 20.9 | -- | * | -- | 20.5 |
| Not Ready to Start Treatment | -- | 45.7 | -- | * | -- | 44.5 |
| Thought They Should Have Been Able to Handle Their Mental Health, Emotions, or Behavior on Their Own | -- | 90.5 | -- | * | -- | 92.8 |
| Thought Their Family, Friends, or Religious Group Would Not Like It if They Got Treatment | -- | 49.4 | -- | * | -- | 52.9 |
| Afraid of Being Committed to Hospital or Forced into Treatment against Their Will | -- | 53.7 | -- | * | -- | 53.4 |
| Thought They Would Be Told They Needed to Take Medication | -- | 46.4 | -- | * | -- | 45.4 |
| Did Not Think Treatment Would Help Them | -- | 58.7 | -- | * | -- | 56.6 |
| Thought No One Would Care if They Got Better | -- | 56.9 | -- | * | -- | 56.6 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple reasons for not receiving mental health treatment; thus, these response categories are not mutually exclusive. Respondents with unknown reason for not receiving treatment data were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Reason Did Not Receive Mental Health Treatment | Among People Aged 12 to 17 with Major Depressive Episode with Severe Impairment Who Did Not Receive Mental Health Treatment and Had a Perceived Unmet Need for Mental Health Treatment in Past Year | |||||
|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
|
| Thought It Would Cost Too Much | -- | 198 | -- | * | -- | 154 |
| Did Not Have Health Insurance Coverage for Mental Health Treatment | -- | 82 | -- | * | -- | 68 |
| Health Insurance Would Not Pay Enough of Costs for Treatment | -- | 85 | -- | * | -- | 64 |
| Did Not Know How or Where to Get Treatment | -- | 258 | -- | * | -- | 195 |
| Could Not Find Treatment Program or Healthcare Professional They Wanted to Go to | -- | 160 | -- | * | -- | 114 |
| No Openings in Treatment Program or with Healthcare Professional They Wanted to Go to | -- | 46 | -- | * | -- | 25 |
| Had Problems with Things Like Transportation, Childcare, or Getting Appointments at Times That Worked for Them | -- | 125 | -- | * | -- | 89 |
| Did Not Have Enough Time for Treatment | -- | 172 | -- | * | -- | 114 |
| Worried That Information Would Not Be Kept Private | -- | 341 | -- | * | -- | 277 |
| Worried about What People Would Think or Say if They Got Treatment | -- | 345 | -- | * | -- | 284 |
| Thought That if People Knew They Were in Treatment, Bad Things Would Happen, Like Losing Their Job, Home, or Children | -- | 119 | -- | * | -- | 93 |
| Not Ready to Start Treatment | -- | 231 | -- | * | -- | 172 |
| Thought They Should Have Been Able to Handle Their Mental Health, Emotions, or Behavior on Their Own | -- | 454 | -- | * | -- | 365 |
| Thought Their Family, Friends, or Religious Group Would Not Like It if They Got Treatment | -- | 247 | -- | * | -- | 211 |
| Afraid of Being Committed to Hospital or Forced into Treatment against Their Will | -- | 284 | -- | * | -- | 221 |
| Thought They Would Be Told They Needed to Take Medication | -- | 247 | -- | * | -- | 189 |
| Did Not Think Treatment Would Help Them | -- | 301 | -- | * | -- | 227 |
| Thought No One Would Care if They Got Better | -- | 308 | -- | * | -- | 242 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple reasons for not receiving mental health treatment; thus, these response categories are not mutually exclusive. Respondents with unknown reason for not receiving treatment data were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. NOTE: Respondents with unknown MDE data or unknown impairment data were excluded. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Reason Did Not Receive Mental Health Treatment | Among People Aged 12 to 17 with Major Depressive Episode with Severe Impairment Who Did Not Receive Mental Health Treatment and Had a Perceived Unmet Need for Mental Health Treatment in Past Year | |||||
|---|---|---|---|---|---|---|
| Any Perceived Unmet Need (2023) |
Any Perceived Unmet Need (2024) |
Sought Treatment (2023) |
Sought Treatment (2024) |
Did Not Seek Treatment but Thought Should Get Treatment (2023) |
Did Not Seek Treatment but Thought Should Get Treatment (2024) |
|
| Thought It Would Cost Too Much | -- | 39.1 | -- | * | -- | 39.1 |
| Did Not Have Health Insurance Coverage for Mental Health Treatment | -- | 17.0 | -- | * | -- | 17.9 |
| Health Insurance Would Not Pay Enough of Costs for Treatment | -- | 17.6 | -- | * | -- | 17.0 |
| Did Not Know How or Where to Get Treatment | -- | 51.4 | -- | * | -- | 50.4 |
| Could Not Find Treatment Program or Healthcare Professional They Wanted to Go to | -- | 32.2 | -- | * | -- | 29.1 |
| No Openings in Treatment Program or with Healthcare Professional They Wanted to Go to | -- | 9.3 | -- | * | -- | 6.4 |
| Had Problems with Things Like Transportation, Childcare, or Getting Appointments at Times That Worked for Them | -- | 25.1 | -- | * | -- | 23.0 |
| Did Not Have Enough Time for Treatment | -- | 34.8 | -- | * | -- | 29.8 |
| Worried That Information Would Not Be Kept Private | -- | 67.4 | -- | * | -- | 70.5 |
| Worried about What People Would Think or Say if They Got Treatment | -- | 68.5 | -- | * | -- | 72.6 |
| Thought That if People Knew They Were in Treatment, Bad Things Would Happen, Like Losing Their Job, Home, or Children | -- | 23.7 | -- | * | -- | 24.0 |
| Not Ready to Start Treatment | -- | 46.3 | -- | * | -- | 44.7 |
| Thought They Should Have Been Able to Handle Their Mental Health, Emotions, or Behavior on Their Own | -- | 89.8 | -- | * | -- | 92.9 |
| Thought Their Family, Friends, or Religious Group Would Not Like It if They Got Treatment | -- | 49.1 | -- | * | -- | 54.1 |
| Afraid of Being Committed to Hospital or Forced into Treatment against Their Will | -- | 56.6 | -- | * | -- | 56.8 |
| Thought They Would Be Told They Needed to Take Medication | -- | 49.2 | -- | * | -- | 48.7 |
| Did Not Think Treatment Would Help Them | -- | 59.7 | -- | * | -- | 58.2 |
| Thought No One Would Care if They Got Better | -- | 61.0 | -- | * | -- | 61.7 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Respondents could indicate multiple reasons for not receiving mental health treatment; thus, these response categories are not mutually exclusive. Respondents with unknown reason for not receiving treatment data were excluded. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. NOTE: Respondents with unknown MDE data or unknown impairment data were excluded. NOTE: Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Substance | Had MDE1,2 (2023) |
Had MDE1,2 (2024) |
Had MDE with Severe Impairment1,3,4 (2023) |
Had MDE with Severe Impairment1,3,4 (2024) |
Had No MDE1,2 (2023) |
Had No MDE1,2 (2024) |
|---|---|---|---|---|---|---|
| ILLICIT DRUGS5 | 1,282 | 1,251 | 1,011 | 982 | 2,372 | 2,506 |
| Marijuana | 990 | 961 | 791 | 767 | 1,777 | 1,648 |
| Cocaine | 27 | 22 | 26 | 21 | 24 | 45 |
| Crack | * | 6 | * | 6 | <1 | 1 |
| Heroin | * | 4 | * | 4 | * | 5 |
| Hallucinogens | 151 | 155 | 143 | 115 | 207 | 247 |
| LSD | 67 | 54 | 62 | 41 | 66 | 56 |
| PCP | 10 | * | 10 | * | 5 | 1 |
| Ecstasy | 18 | 26 | 18 | 23 | 33 | 31 |
| Psilocybin | -- | 120 | -- | 100 | -- | 188 |
| Inhalants6 | -- | 275 | -- | 219 | -- | 628 |
| Methamphetamine | 17 | 7 | 17 | 6 | 17 | 49 |
| Misuse of Prescription Psychotherapeutics | 278 | 217 | 228 | 173 | 480 | 407 |
| Pain Relievers | 159 | 122 | 137 | 112 | 389 | 287 |
| Prescription Opioids | 138 | 102 | 119 | 92 | 350 | 277 |
| Stimulants | 123 | 67 | 107a | 49 | 97 | 129 |
| Tranquilizers or Sedatives | 89 | 93 | 70 | 65 | 76 | 77 |
| Tranquilizers | 66 | 68 | 53 | 48 | 47 | 57 |
| Sedatives | 29 | 31 | 23 | 22 | 36 | 32 |
| Benzodiazepines | 64 | 49 | 53 | 46 | 41 | 57 |
| Opioids5,7 | 138 | 106 | 119 | 97 | 350 | 277 |
| Central Nervous System Stimulants | 132 | 84 | 116 | 65 | 135 | 197 |
| Illicit Drugs Other Than Marijuana5,6,8 | -- | 554 | -- | 434 | -- | 1,192 |
| TOBACCO PRODUCT USE OR NICOTINE VAPING9 | 1,205 | 1,115 | 999 | 855 | 2,352 | 2,224 |
| Tobacco Products9 | 390 | 414 | 320 | 317 | 796 | 786 |
| Cigarettes | 327 | 295 | 271 | 224 | 514 | 485 |
| Daily Cigarettes | -- | -- | -- | -- | -- | -- |
| Smokeless Tobacco | 39a | 91 | 20b | 70 | 162 | 185 |
| Cigars | 87 | 137 | 74 | 113 | 296 | 315 |
| Pipe Tobacco9 | -- | -- | -- | -- | -- | -- |
| Nicotine Vaping | 1,155 | 1,050 | 957 | 819 | 2,134 | 2,042 |
| ALCOHOL | 1,429a | 1,190 | 1,108 | 929 | 2,799 | 2,956 |
| Binge Alcohol Use | -- | -- | -- | -- | -- | -- |
| Heavy Alcohol Use | -- | -- | -- | -- | -- | -- |
| OPIOIDS INCLUDING ILLEGALLY MADE FENTANYL7 | 139 | 106 | 120 | 97 | 358 | 309 |
| Illegally Made Fentanyl | 21 | * | 21 | * | 13 | 38 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Respondents with unknown past year major depressive episode (MDE) data were excluded. 3 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 4 Respondents with unknown MDE data or unknown impairment data were excluded. 5 Does not include illegally made fentanyl (IMF). 6 Changes were made to the inhalant questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 7 Some 2023 estimates may differ from previously published estimates due to updates in how opioids are defined beginning in 2024. See Chapter 4 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 8 Illicit drugs other than marijuana excludes respondents who used only marijuana but includes those who used marijuana in addition to other illicit drugs. 9 Information about past year use of pipe tobacco was not collected. Tobacco product use (as well as tobacco product use or nicotine vaping) in the past year exclude past year pipe tobacco use, but include past month pipe tobacco use. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Substance | Had MDE1,2 (2023) |
Had MDE1,2 (2024) |
Had MDE with Severe Impairment1,3,4 (2023) |
Had MDE with Severe Impairment1,3,4 (2024) |
Had No MDE1,2 (2023) |
Had No MDE1,2 (2024) |
|---|---|---|---|---|---|---|
| ILLICIT DRUGS5 | 28.4a | 32.6 | 30.1 | 34.6 | 11.6 | 11.8 |
| Marijuana | 21.9 | 25.0 | 23.6 | 27.0 | 8.7 | 7.8 |
| Cocaine | 0.6 | 0.6 | 0.8 | 0.7 | 0.1 | 0.2 |
| Crack | * | 0.2 | * | 0.2 | <0.1 | <0.1 |
| Heroin | * | 0.1 | * | 0.2 | * | <0.1 |
| Hallucinogens | 3.3 | 4.0 | 4.3 | 4.1 | 1.0 | 1.2 |
| LSD | 1.5 | 1.4 | 1.8 | 1.4 | 0.3 | 0.3 |
| PCP | 0.2 | * | 0.3 | * | <0.1 | <0.1 |
| Ecstasy | 0.4 | 0.7 | 0.5 | 0.8 | 0.2 | 0.1 |
| Psilocybin | -- | 3.1 | -- | 3.5 | -- | 0.9 |
| Inhalants6 | -- | 7.1 | -- | 7.7 | -- | 3.0 |
| Methamphetamine | 0.4 | 0.2 | 0.5 | 0.2 | 0.1 | 0.2 |
| Misuse of Prescription Psychotherapeutics | 6.2 | 5.6 | 6.8 | 6.1 | 2.4 | 1.9 |
| Pain Relievers | 3.5 | 3.2 | 4.1 | 3.9 | 1.9a | 1.4 |
| Prescription Opioids | 3.1 | 2.7 | 3.5 | 3.3 | 1.7 | 1.3 |
| Stimulants | 2.7 | 1.7 | 3.2 | 1.7 | 0.5 | 0.6 |
| Tranquilizers or Sedatives | 2.0 | 2.4 | 2.1 | 2.3 | 0.4 | 0.4 |
| Tranquilizers | 1.5 | 1.8 | 1.6 | 1.7 | 0.2 | 0.3 |
| Sedatives | 0.6 | 0.8 | 0.7 | 0.8 | 0.2 | 0.2 |
| Benzodiazepines | 1.4 | 1.3 | 1.6 | 1.6 | 0.2 | 0.3 |
| Opioids5,7 | 3.1 | 2.8 | 3.5 | 3.4 | 1.7 | 1.3 |
| Central Nervous System Stimulants | 2.9 | 2.2 | 3.4 | 2.3 | 0.7 | 0.9 |
| Illicit Drugs Other Than Marijuana5,6,8 | -- | 14.4 | -- | 15.3 | -- | 5.6 |
| TOBACCO PRODUCT USE OR NICOTINE VAPING9 | 26.7 | 29.0 | 29.7 | 30.2 | 11.5 | 10.5 |
| Tobacco Products9 | 8.6 | 10.8 | 9.5 | 11.2 | 3.9 | 3.7 |
| Cigarettes | 7.3 | 7.7 | 8.1 | 7.9 | 2.5 | 2.3 |
| Daily Cigarettes | -- | -- | -- | -- | -- | -- |
| Smokeless Tobacco | 0.9b | 2.4 | 0.6b | 2.5 | 0.8 | 0.9 |
| Cigars | 1.9a | 3.6 | 2.2 | 4.0 | 1.5 | 1.5 |
| Pipe Tobacco9 | -- | -- | -- | -- | -- | -- |
| Nicotine Vaping | 25.6 | 27.4 | 28.5 | 28.9 | 10.5 | 9.6 |
| ALCOHOL | 31.6 | 31.0 | 33.0 | 32.8 | 13.7 | 14.0 |
| Binge Alcohol Use | -- | -- | -- | -- | -- | -- |
| Heavy Alcohol Use | -- | -- | -- | -- | -- | -- |
| OPIOIDS INCLUDING ILLEGALLY MADE FENTANYL7 | 3.1 | 2.8 | 3.6 | 3.4 | 1.8 | 1.5 |
| Illegally Made Fentanyl | 0.5 | * | 0.6 | * | 0.1 | 0.2 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Respondents with unknown past year major depressive episode (MDE) data were excluded. 3 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 4 Respondents with unknown MDE data or unknown impairment data were excluded. 5 Does not include illegally made fentanyl (IMF). 6 Changes were made to the inhalant questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 7 Some 2023 estimates may differ from previously published estimates due to updates in how opioids are defined beginning in 2024. See Chapter 4 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 8 Illicit drugs other than marijuana excludes respondents who used only marijuana but includes those who used marijuana in addition to other illicit drugs. 9 Information about past year use of pipe tobacco was not collected. Tobacco product use (as well as tobacco product use or nicotine vaping) in the past year exclude past year pipe tobacco use, but include past month pipe tobacco use. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Substance Use Disorder/Age Group | Total (2023) |
Total (2024) |
Male (2023) |
Male (2024) |
Female (2023) |
Female (2024) |
|---|---|---|---|---|---|---|
| SUBSTANCE USE DISORDER | 856 | 792 | 178 | 247 | 678 | 545 |
| 12-13 | 61 | * | 4 | * | * | * |
| 14-15 | 280 | 217 | 50 | * | 230 | 166 |
| 16-17 | 515 | 506 | 124 | 191 | 391 | 315 |
| Drug Use Disorder | 712 | 696 | 154 | 217 | 559 | 479 |
| 12-13 | 58 | * | * | * | * | * |
| 14-15 | 243 | 197 | 46 | * | 197 | 147 |
| 16-17 | 411 | 436 | 103 | 161 | 308 | 275 |
| Alcohol Use Disorder | 341 | 328 | 63 | 76 | 279 | 251 |
| 12-13 | * | * | * | * | * | * |
| 14-15 | * | * | * | * | * | * |
| 16-17 | 221 | 220 | * | * | 181 | * |
| NO SUBSTANCE USE DISORDER | 3,660b | 3,047 | 1,029a | 834 | 2,631b | 2,213 |
| 12-13 | 834 | 698 | 206 | 156 | 628 | 542 |
| 14-15 | 1,402a | 1,149 | 419a | 294 | 983 | 855 |
| 16-17 | 1,424a | 1,201 | 404 | 384 | 1,020a | 816 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Substance Use Disorder/Age Group | Total (2023) |
Total (2024) |
Male (2023) |
Male (2024) |
Female (2023) |
Female (2024) |
|---|---|---|---|---|---|---|
| SUBSTANCE USE DISORDER | 41.1 | 41.0 | 21.9 | 30.0 | 53.2 | 49.2 |
| 12-13 | 33.2 | * | 5.6 | * | * | * |
| 14-15 | 36.9 | 41.5 | 16.4 | * | 50.5 | 47.1 |
| 16-17 | 45.1 | 41.9 | 28.3 | 32.7 | 55.6 | 50.6 |
| Drug Use Disorder | 42.2 | 42.8 | 23.9 | 30.7 | 53.5 | 52.3 |
| 12-13 | 36.0 | * | * | * | * | * |
| 14-15 | 38.9 | 44.0 | 18.9 | * | 51.8 | 49.2 |
| 16-17 | 45.7 | 43.7 | 30.8 | 33.1 | 54.5 | 54.0 |
| Alcohol Use Disorder | 47.1 | 44.3 | 24.7 | 30.9 | 59.2 | 51.0 |
| 12-13 | * | * | * | * | * | * |
| 14-15 | * | * | * | * | * | * |
| 16-17 | 50.7 | 45.1 | * | * | 62.9 | * |
| NO SUBSTANCE USE DISORDER | 16.0b | 13.2 | 8.6a | 7.0 | 24.3b | 20.0 |
| 12-13 | 11.3a | 9.4 | 5.1 | 4.1 | 18.9a | 15.0 |
| 14-15 | 17.4a | 14.3 | 10.0a | 6.9 | 25.4 | 22.7 |
| 16-17 | 19.2b | 15.7 | 10.7 | 9.7 | 28.0b | 22.1 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Substance Use Disorder/Age Group | Total (2023) |
Total (2024) |
Male (2023) |
Male (2024) |
Female (2023) |
Female (2024) |
|---|---|---|---|---|---|---|
| SUBSTANCE USE DISORDER | 717 | 632 | 144 | 204 | 573a | 428 |
| 12-13 | 51 | * | * | * | * | * |
| 14-15 | 248a | 158 | 42 | * | 206a | 126 |
| 16-17 | 418 | 413 | 99 | 166 | 319 | 247 |
| Drug Use Disorder | 602 | 557 | 122 | 181 | 480 | 376 |
| 12-13 | 48 | * | * | * | * | * |
| 14-15 | 217a | 145 | 40 | * | 177a | 112 |
| 16-17 | 337 | 357 | 79 | 143 | 258 | 214 |
| Alcohol Use Disorder | 287 | 265 | 51 | 61 | 236 | 204 |
| 12-13 | * | * | * | * | * | * |
| 14-15 | * | 60 | * | * | * | * |
| 16-17 | 178 | 177 | * | * | * | 121 |
| NO SUBSTANCE USE DISORDER | 2,641b | 2,202 | 701a | 531 | 1,940a | 1,671 |
| 12-13 | 567 | 507 | 136 | 102 | 432 | 405 |
| 14-15 | 1,039a | 842 | 293a | 182 | 745 | 660 |
| 16-17 | 1,035 | 854 | 272 | 248 | 763 | 606 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. NOTE: Respondents with unknown MDE data or unknown impairment data were excluded. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Substance Use Disorder/Age Group | Total (2023) |
Total (2024) |
Male (2023) |
Male (2024) |
Female (2023) |
Female (2024) |
|---|---|---|---|---|---|---|
| SUBSTANCE USE DISORDER | 34.5 | 32.8 | 17.7 | 24.7 | 45.2 | 38.9 |
| 12-13 | 27.8 | * | * | * | * | * |
| 14-15 | 32.8 | 30.3 | 14.0 | * | 45.4 | 35.6 |
| 16-17 | 36.6 | 34.4 | 22.5 | 28.4 | 45.4 | 40.1 |
| Drug Use Disorder | 35.8 | 34.4 | 19.0 | 25.5 | 46.1 | 41.4 |
| 12-13 | 29.8 | * | * | * | * | * |
| 14-15 | 34.9 | 32.2 | 16.4 | * | 47.0 | 37.6 |
| 16-17 | 37.4 | 36.0 | 23.6 | 29.3 | 45.6 | 42.5 |
| Alcohol Use Disorder | 39.8 | 35.9 | 20.2 | 24.9 | 50.4 | 41.4 |
| 12-13 | * | * | * | * | * | * |
| 14-15 | * | 30.8 | * | * | * | * |
| 16-17 | 40.8 | 36.3 | * | * | * | 41.0 |
| NO SUBSTANCE USE DISORDER | 11.6b | 9.6 | 5.8a | 4.4 | 17.9b | 15.1 |
| 12-13 | 7.7 | 6.8 | 3.4 | 2.7 | 13.0 | 11.2 |
| 14-15 | 12.9a | 10.5 | 7.0a | 4.3 | 19.3 | 17.6 |
| 16-17 | 14.0a | 11.2 | 7.2 | 6.3 | 20.9a | 16.4 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. NOTE: Respondents with unknown MDE data or unknown impairment data were excluded. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| MDE/Demographic Characteristic | No Substance Use Disorder | No Substance Use Disorder | Substance Use Disorder | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drugs | Drugs | Marijuana | Marijuana | Opioids1 | Opioids1 | Alcohol | Alcohol | Both Drugs and Alcohol | Both Drugs and Alcohol | Substance Use Disorder | Substance Use Disorder | |||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| TOTAL2 | 23,723 | 23,928 | 1,780 | 1,705 | 1,223 | 1,219 | 230 | 267 | 757 | 775 | 345 | 456 | 2,192 | 2,024 |
| MDE3,4 | 3,660b | 3,047 | 712 | 696 | 481 | 511 | 81 | 107 | 341 | 328 | 198 | 231 | 856 | 792 |
| Age Group | ||||||||||||||
| 12-13 | 834 | 698 | 58 | 62 | 24 | 30 | 15 | 27 | 9 | 30 | 6 | 23 | 61 | 69 |
| 14-15 | 1,402a | 1,149 | 243 | 197 | 141 | 135 | 39 | 33 | 112 | 77 | 75 | 57 | 280 | 217 |
| 16-17 | 1,424a | 1,201 | 411 | 436 | 316 | 346 | 27 | 47 | 221 | 220 | 117 | 151 | 515 | 506 |
| Sex | ||||||||||||||
| Male | 1,029a | 834 | 154 | 217 | 115 | 154 | 16 | 28 | 63 | 76 | 38 | 46 | 178 | 247 |
| Female | 2,631b | 2,213 | 559 | 479 | 366 | 357 | 65 | 79 | 279 | 251 | 159 | 185 | 678 | 545 |
| MDE with Severe Impairment5,6 | 2,641b | 2,202 | 602 | 557 | 401 | 409 | 62 | 94 | 287 | 265 | 172 | 191 | 717 | 632 |
| Age Group | ||||||||||||||
| 12-13 | 567 | 507 | 48 | 56 | 21 | 27 | 12 | 24 | 9 | 28 | 6 | 22 | 51 | 61 |
| 14-15 | 1,039a | 842 | 217a | 145 | 125 | 93 | 26 | 32 | 101 | 60 | 70 | 47 | 248a | 158 |
| 16-17 | 1,035 | 854 | 337 | 357 | 254 | 289 | 25 | 38 | 178 | 177 | 96 | 122 | 418 | 413 |
| Sex | ||||||||||||||
| Male | 701a | 531 | 122 | 181 | 89 | 127 | 15 | 27 | 51 | 61 | 29 | 38 | 144 | 204 |
| Female | 1,940a | 1,671 | 480 | 376 | 311 | 282 | 47 | 67 | 236 | 204 | 143 | 153 | 573a | 428 |
| NO MDE3,4 | 19,171 | 20,020 | 975 | 928 | 668 | 656 | 137 | 150 | 383 | 411 | 128 | 199 | 1,229 | 1,141 |
| Age Group | ||||||||||||||
| 12-13 | 6,519 | 6,717 | 104 | 116 | 21 | 29 | 44 | 44 | 21 | 24 | 1 | 5 | 123 | 135 |
| 14-15 | 6,663 | 6,861 | 382a | 251 | 240a | 155 | 48 | 51 | 147 | 119 | 51 | 64 | 479b | 306 |
| 16-17 | 5,989 | 6,442 | 489 | 561 | 407 | 471 | 45 | 55 | 215 | 268 | 76 | 130 | 627 | 700 |
| Sex | ||||||||||||||
| Male | 10,958 | 11,157 | 488 | 492 | 330 | 353 | 60 | 48 | 190 | 170 | 45 | 83 | 634 | 579 |
| Female | 8,213a | 8,863 | 486 | 437 | 338 | 302 | 77 | 102 | 192 | 241 | 83 | 115 | 596 | 563 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Some 2023 estimates may differ from previously published estimates due to updates in how opioids are defined beginning in 2024. See Chapter 4 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 2 The total row includes respondents with unknown past year MDE data. 3 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 4 Respondents with unknown past year major depressive episode (MDE) data were excluded. 5 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 6 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||||||
| MDE/Demographic Characteristic | No Substance Use Disorder | No Substance Use Disorder | Substance Use Disorder | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drugs | Drugs | Marijuana | Marijuana | Opioids1 | Opioids1 | Alcohol | Alcohol | Both Drugs and Alcohol | Both Drugs and Alcohol | Substance Use Disorder | Substance Use Disorder | |||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| TOTAL2 | 91.5 | 92.2 | 6.9 | 6.6 | 4.7 | 4.7 | 0.9 | 1.0 | 2.9 | 3.0 | 1.3 | 1.8 | 8.5 | 7.8 |
| MDE3,4 | 81.0 | 79.4 | 15.8 | 18.1 | 10.7 | 13.3 | 1.8 | 2.8 | 7.6 | 8.5 | 4.4 | 6.0 | 19.0 | 20.6 |
| Age Group | ||||||||||||||
| 12-13 | 93.1 | 91.0 | 6.5 | 8.1 | 2.7 | 4.0 | 1.7 | 3.5 | 1.0 | 3.9 | 0.6 | 3.0 | 6.9 | 9.0 |
| 14-15 | 83.4 | 84.1 | 14.5 | 14.5 | 8.4 | 9.9 | 2.3 | 2.4 | 6.6 | 5.7 | 4.5 | 4.2 | 16.6 | 15.9 |
| 16-17 | 73.4 | 70.4 | 21.2 | 25.6 | 16.3 | 20.3 | 1.4 | 2.7 | 11.4 | 12.9 | 6.0 | 8.8 | 26.6 | 29.6 |
| Sex | ||||||||||||||
| Male | 85.2a | 77.1 | 12.7a | 20.1 | 9.5 | 14.3 | 1.3 | 2.6 | 5.2 | 7.0 | 3.2 | 4.3 | 14.8a | 22.9 |
| Female | 79.5 | 80.2 | 16.9 | 17.4 | 11.1 | 12.9 | 2.0 | 2.9 | 8.4 | 9.1 | 4.8 | 6.7 | 20.5 | 19.8 |
| MDE with Severe Impairment5,6 | 78.6 | 77.7 | 17.9 | 19.7 | 11.9 | 14.4 | 1.9 | 3.3 | 8.6 | 9.4 | 5.1 | 6.7 | 21.4 | 22.3 |
| Age Group | ||||||||||||||
| 12-13 | 91.8 | 89.3 | 7.7 | 9.8 | 3.4 | 4.8 | 1.9 | 4.2 | 1.5 | 4.9 | 0.9 | 4.0 | 8.2 | 10.7 |
| 14-15 | 80.7 | 84.2 | 16.9 | 14.5 | 9.7 | 9.3 | 2.0 | 3.2 | 7.8 | 6.0 | 5.4 | 4.7 | 19.3 | 15.8 |
| 16-17 | 71.2 | 67.4 | 23.2 | 28.2 | 17.5 | 22.8 | 1.7 | 3.0 | 12.2 | 14.0 | 6.6 | 9.6 | 28.8 | 32.6 |
| Sex | ||||||||||||||
| Male | 83.0a | 72.3 | 14.4a | 24.6 | 10.6 | 17.3 | 1.8 | 3.6 | 6.0 | 8.3 | 3.4 | 5.2 | 17.0a | 27.7 |
| Female | 77.2 | 79.6 | 19.1 | 17.9 | 12.4 | 13.4 | 1.9 | 3.2 | 9.4 | 9.7 | 5.7 | 7.3 | 22.8 | 20.4 |
| NO MDE3,4 | 94.0 | 94.6 | 4.8 | 4.4 | 3.3 | 3.1 | 0.7 | 0.7 | 1.9 | 1.9 | 0.6 | 0.9 | 6.0 | 5.4 |
| Age Group | ||||||||||||||
| 12-13 | 98.1 | 98.0 | 1.6 | 1.7 | 0.3 | 0.4 | 0.7 | 0.6 | 0.3 | 0.4 | <0.1 | 0.1 | 1.9 | 2.0 |
| 14-15 | 93.3b | 95.7 | 5.3b | 3.5 | 3.4a | 2.2 | 0.7 | 0.7 | 2.1 | 1.7 | 0.7 | 0.9 | 6.7b | 4.3 |
| 16-17 | 90.5 | 90.2 | 7.4 | 7.9 | 6.1 | 6.6 | 0.7 | 0.8 | 3.2 | 3.8 | 1.2 | 1.8 | 9.5 | 9.8 |
| Sex | ||||||||||||||
| Male | 94.5 | 95.1 | 4.2 | 4.2 | 2.8 | 3.0 | 0.5 | 0.4 | 1.6 | 1.4 | 0.4 | 0.7 | 5.5 | 4.9 |
| Female | 93.2 | 94.0 | 5.5 | 4.6 | 3.8 | 3.2 | 0.9 | 1.1 | 2.2 | 2.6 | 0.9 | 1.2 | 6.8 | 6.0 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Some 2023 estimates may differ from previously published estimates due to updates in how opioids are defined beginning in 2024. See Chapter 4 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. 2 The total row includes respondents with unknown past year MDE data. 3 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 4 Respondents with unknown past year major depressive episode (MDE) data were excluded. 5 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 6 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||||||
| Demographic Characteristic | Substance Use Disorder or MDE1,2 (2023) |
Substance Use Disorder or MDE1,2 (2024) |
Substance Use Disorder or MDE with Severe Impairment1,3,4 (2023) |
Substance Use Disorder or MDE with Severe Impairment1,3,4 (2024) |
|---|---|---|---|---|
| TOTAL | 5,852b | 5,071 | 4,832b | 4,226 |
| AGE GROUP | ||||
| 12-13 | 1,054 | 937 | 787 | 745 |
| 14-15 | 2,191b | 1,699 | 1,827b | 1,392 |
| 16-17 | 2,607 | 2,435 | 2,218 | 2,089 |
| SEX | ||||
| Male | 1,881 | 1,694 | 1,553 | 1,391 |
| Female | 3,971b | 3,377 | 3,279b | 2,835 |
| HISPANIC ORIGIN AND RACE | ||||
| Not Hispanic or Latino | 4,231b | 3,713 | 3,469b | 3,074 |
| AIAN | 54 | 27 | 32 | 23 |
| Asian | 237 | 208 | 177 | 172 |
| Black or African American | 650 | 579 | 549 | 499 |
| NHPI | * | 2 | * | 2 |
| White | 3,007a | 2,592 | 2,470a | 2,130 |
| Two or More Races | 275 | 305 | 236 | 247 |
| Hispanic or Latino | 1,621a | 1,358 | 1,364 | 1,152 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Respondents with unknown past year major depressive episode (MDE) data were excluded. 3 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 4 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||
| Demographic Characteristic | Substance Use Disorder or MDE1,2 (2023) |
Substance Use Disorder or MDE1,2 (2024) |
Substance Use Disorder or MDE with Severe Impairment1,3,4 (2023) |
Substance Use Disorder or MDE with Severe Impairment1,3,4 (2024) |
|---|---|---|---|---|
| TOTAL | 23.4b | 20.2 | 19.3b | 16.8 |
| AGE GROUP | ||||
| 12-13 | 13.9 | 12.2 | 10.4 | 9.7 |
| 14-15 | 24.7b | 19.8 | 20.7b | 16.3 |
| 16-17 | 30.3 | 27.4 | 25.8 | 23.5 |
| SEX | ||||
| Male | 14.7 | 13.2 | 12.1 | 10.8 |
| Female | 32.6b | 27.6 | 26.9b | 23.2 |
| HISPANIC ORIGIN AND RACE | ||||
| Not Hispanic or Latino | 22.9b | 20.1 | 18.8b | 16.7 |
| AIAN | 23.6 | 13.6 | 13.9 | 11.6 |
| Asian | 16.9 | 14.4 | 12.6 | 11.9 |
| Black or African American | 18.8 | 16.7 | 15.9 | 14.4 |
| NHPI | * | 3.4 | * | 3.0 |
| White | 24.2b | 21.1 | 19.9a | 17.4 |
| Two or More Races | 30.4 | 30.2 | 26.1 | 24.6 |
| Hispanic or Latino | 24.8a | 20.5 | 20.9a | 17.4 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Respondents with unknown past year major depressive episode (MDE) data were excluded. 3 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 4 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||
| Co-Occurring Substance Use Disorder and MDE | Total (2023) |
Total (2024) |
Male (2023) |
Male (2024) |
Female (2023) |
Female (2024) |
|---|---|---|---|---|---|---|
| Substance Use Disorder and MDE | 856 | 792 | 178 | 247 | 678a | 545 |
| Substance Use Disorder and MDE with Severe Impairment1,2 | 717 | 632 | 144 | 204 | 573a | 428 |
| Drug Use Disorder and MDE | 712 | 696 | 154 | 217 | 559 | 479 |
| Drug Use Disorder and MDE with Severe Impairment1,2 | 602 | 557 | 122 | 181 | 480 | 376 |
| Alcohol Use Disorder and MDE | 341 | 328 | 63 | 76 | 279 | 251 |
| Alcohol Use Disorder and MDE with Severe Impairment1,2 | 287 | 265 | 51 | 61 | 236 | 204 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 2 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Co-Occurring Substance Use Disorder and MDE | Total (2023) |
Total (2024) |
Male (2023) |
Male (2024) |
Female (2023) |
Female (2024) |
|---|---|---|---|---|---|---|
| Substance Use Disorder and MDE | 3.4 | 3.2 | 1.4 | 1.9 | 5.6a | 4.5 |
| Substance Use Disorder and MDE with Severe Impairment1,2 | 2.9 | 2.5 | 1.1 | 1.6 | 4.7a | 3.5 |
| Drug Use Disorder and MDE | 2.9 | 2.8 | 1.2 | 1.7 | 4.6 | 3.9 |
| Drug Use Disorder and MDE with Severe Impairment1,2 | 2.4 | 2.2 | 1.0 | 1.4 | 4.0 | 3.1 |
| Alcohol Use Disorder and MDE | 1.4 | 1.3 | 0.5 | 0.6 | 2.3 | 2.1 |
| Alcohol Use Disorder and MDE with Severe Impairment1,2 | 1.2 | 1.1 | 0.4 | 0.5 | 2.0 | 1.7 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 2 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Substance Use Disorder Severity Level | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | 25,915 | 25,952 | 4,517b | 3,840 | 3,358b | 2,834 | 20,400 | 21,161 |
| Substance Use Disorder | 2,192 | 2,024 | 856 | 792 | 717 | 632 | 1,229 | 1,141 |
| Mild SUD | 1,224a | 992 | 395 | 329 | 309 | 252 | 772 | 613 |
| Moderate SUD | 446 | 496 | 191 | 197 | 163 | 157 | 231 | 274 |
| Severe SUD | 522 | 535 | 270 | 267 | 245 | 222 | 225 | 254 |
| No SUD | 23,723 | 23,928 | 3,660b | 3,047 | 2,641b | 2,202 | 19,171 | 20,020 |
| Drug Use Disorder | 1,780 | 1,705 | 712 | 696 | 602 | 557 | 975 | 928 |
| Mild SUD | 968 | 830 | 304 | 284 | 241 | 221 | 618 | 502 |
| Moderate SUD | 367 | 420 | 175 | 185 | 147 | 147 | 171 | 212 |
| Severe SUD | 445 | 455 | 233 | 227 | 214 | 189 | 186 | 215 |
| No SUD | 24,135 | 24,247 | 3,804b | 3,144 | 2,756b | 2,277 | 19,425 | 20,232 |
| Marijuana Use Disorder | 1,223 | 1,219 | 481 | 511 | 401 | 409 | 668 | 656 |
| Mild SUD | 546 | 437 | 165 | 151 | 126 | 118 | 351 | 266 |
| Moderate SUD | 284 | 368 | 126 | 146 | 103 | 113 | 141 | 203 |
| Severe SUD | 392 | 414 | 190 | 215 | 171 | 179 | 176 | 186 |
| No SUD | 24,693 | 24,732 | 4,035b | 3,328 | 2,957b | 2,425 | 19,732 | 20,505 |
| Opioid Use Disorder6 | 230 | 267 | 81 | 107 | 62 | 94 | 137 | 150 |
| Mild SUD | 174 | 210 | 55 | 75 | 40 | 69 | 114 | 126 |
| Moderate SUD | 23 | 28 | 9 | 20 | 6 | 15 | 12 | 8 |
| Severe SUD | 33 | 28 | 16 | 11 | 16 | 9 | 11 | 17 |
| No SUD | 25,685 | 25,685 | 4,436b | 3,733 | 3,295b | 2,740 | 20,263 | 21,011 |
| Alcohol Use Disorder | 757 | 775 | 341 | 328 | 287 | 265 | 383 | 411 |
| Mild SUD | 488 | 406 | 222 | 172 | 188 | 131 | 247 | 222 |
| Moderate SUD | 135a | 220 | 49 | 84 | 36 | 72 | 82 | 119 |
| Severe SUD | 134 | 149 | 70 | 72 | 64 | 63 | 54 | 70 |
| No SUD | 25,159 | 25,176 | 4,175b | 3,512 | 3,070b | 2,569 | 20,017 | 20,750 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Some 2023 estimates may differ from previously published estimates due to updates in how opioids are defined beginning in 2024. See Chapter 4 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Substance Use Disorder Severity Level | Aged 12-171 (2023) |
Aged 12-171 (2024) |
Had MDE2,3 (2023) |
Had MDE2,3 (2024) |
Had MDE with Severe Impairment2,4,5 (2023) |
Had MDE with Severe Impairment2,4,5 (2024) |
No MDE2,3 (2023) |
No MDE2,3 (2024) |
|---|---|---|---|---|---|---|---|---|
| TOTAL | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Substance Use Disorder | 8.5 | 7.8 | 19.0 | 20.6 | 21.4 | 22.3 | 6.0 | 5.4 |
| Mild SUD | 4.7a | 3.8 | 8.7 | 8.6 | 9.2 | 8.9 | 3.8a | 2.9 |
| Moderate SUD | 1.7 | 1.9 | 4.2 | 5.1 | 4.9 | 5.6 | 1.1 | 1.3 |
| Severe SUD | 2.0 | 2.1 | 6.0 | 7.0 | 7.3 | 7.8 | 1.1 | 1.2 |
| No SUD | 91.5 | 92.2 | 81.0 | 79.4 | 78.6 | 77.7 | 94.0 | 94.6 |
| Drug Use Disorder | 6.9 | 6.6 | 15.8 | 18.1 | 17.9 | 19.7 | 4.8 | 4.4 |
| Mild SUD | 3.7 | 3.2 | 6.7 | 7.4 | 7.2 | 7.8 | 3.0 | 2.4 |
| Moderate SUD | 1.4 | 1.6 | 3.9 | 4.8 | 4.4 | 5.2 | 0.8 | 1.0 |
| Severe SUD | 1.7 | 1.8 | 5.2 | 5.9 | 6.4 | 6.7 | 0.9 | 1.0 |
| No SUD | 93.1 | 93.4 | 84.2 | 81.9 | 82.1 | 80.3 | 95.2 | 95.6 |
| Marijuana Use Disorder | 4.7 | 4.7 | 10.7 | 13.3 | 11.9 | 14.4 | 3.3 | 3.1 |
| Mild SUD | 2.1 | 1.7 | 3.6 | 3.9 | 3.8 | 4.2 | 1.7 | 1.3 |
| Moderate SUD | 1.1 | 1.4 | 2.8 | 3.8 | 3.1 | 4.0 | 0.7 | 1.0 |
| Severe SUD | 1.5 | 1.6 | 4.2 | 5.6 | 5.1 | 6.3 | 0.9 | 0.9 |
| No SUD | 95.3 | 95.3 | 89.3 | 86.7 | 88.1 | 85.6 | 96.7 | 96.9 |
| Opioid Use Disorder6 | 0.9 | 1.0 | 1.8 | 2.8 | 1.9 | 3.3 | 0.7 | 0.7 |
| Mild SUD | 0.7 | 0.8 | 1.2 | 2.0 | 1.2 | 2.4 | 0.6 | 0.6 |
| Moderate SUD | 0.1 | 0.1 | 0.2 | 0.5 | 0.2 | 0.5 | 0.1 | <0.1 |
| Severe SUD | 0.1 | 0.1 | 0.4 | 0.3 | 0.5 | 0.3 | 0.1 | 0.1 |
| No SUD | 99.1 | 99.0 | 98.2 | 97.2 | 98.1 | 96.7 | 99.3 | 99.3 |
| Alcohol Use Disorder | 2.9 | 3.0 | 7.6 | 8.5 | 8.6 | 9.4 | 1.9 | 1.9 |
| Mild SUD | 1.9 | 1.6 | 4.9 | 4.5 | 5.6 | 4.6 | 1.2 | 1.1 |
| Moderate SUD | 0.5a | 0.8 | 1.1 | 2.2 | 1.1a | 2.5 | 0.4 | 0.6 |
| Severe SUD | 0.5 | 0.6 | 1.5 | 1.9 | 1.9 | 2.2 | 0.3 | 0.3 |
| No SUD | 97.1 | 97.0 | 92.4 | 91.5 | 91.4 | 90.6 | 98.1 | 98.1 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 The aged 12-17 column includes respondents with unknown MDE data and respondents with unknown MDE with severe impairment data. 2 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 3 Respondents with unknown past year major depressive episode (MDE) data were excluded. 4 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 5 Respondents with unknown MDE data or unknown impairment data were excluded. 6 Some 2023 estimates may differ from previously published estimates due to updates in how opioids are defined beginning in 2024. See Chapter 4 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Substance Use Disorder/MDE/Age Group | Received Substance Use Treatment (SU Tx) OR Mental Health Treatment (MH Tx) (2023) |
Received Substance Use Treatment (SU Tx) OR Mental Health Treatment (MH Tx) (2024) |
Received SU Tx BUT NOT MH Tx (2023) |
Received SU Tx BUT NOT MH Tx (2024) |
Received MH Tx BUT NOT SU Tx (2023) |
Received MH Tx BUT NOT SU Tx (2024) |
Received SU Tx AND MH Tx (2023) |
Received SU Tx AND MH Tx (2024) |
Received NEITHER SU Tx NOR MH Tx (2023) |
Received NEITHER SU Tx NOR MH Tx (2024) |
|---|---|---|---|---|---|---|---|---|---|---|
| Substance Use Disorder and MDE | -- | 571 | -- | 8 | -- | 420 | -- | 143 | -- | 221 |
| 12-13 | -- | * | -- | * | -- | * | -- | * | -- | * |
| 14-15 | -- | 157 | -- | <1 | -- | * | -- | 46 | -- | 60 |
| 16-17 | -- | 353 | -- | 2 | -- | 260 | -- | 91 | -- | 152 |
| Substance Use Disorder and MDE with Severe Impairment1,2 | -- | 467 | -- | 7 | -- | 330 | -- | 130 | -- | 165 |
| 12-13 | -- | * | -- | * | -- | * | -- | * | -- | * |
| 14-15 | -- | * | -- | * | -- | 66 | -- | 44 | -- | * |
| 16-17 | -- | 304 | -- | 2 | -- | 221 | -- | 81 | -- | 109 |
| Substance Use Disorder and No MDE | -- | 484 | -- | 45 | -- | 327 | -- | 112 | -- | 657 |
| 12-13 | -- | * | -- | * | -- | * | -- | 17 | -- | * |
| 14-15 | -- | 153 | -- | 16 | -- | 102 | -- | 35 | -- | 153 |
| 16-17 | -- | 237 | -- | 24 | -- | 152 | -- | 60 | -- | 463 |
| MDE and No Substance Use Disorder | -- | 1,784 | -- | 21 | -- | 1,711 | -- | 53 | -- | 1,264 |
| 12-13 | -- | 411 | -- | <1 | -- | 401 | -- | 10 | -- | 287 |
| 14-15 | -- | 688 | -- | 4 | -- | 656 | -- | 28 | -- | 460 |
| 16-17 | -- | 685 | -- | 16 | -- | 654 | -- | 15 | -- | 516 |
| No Substance Use Disorder and No MDE | -- | 4,422 | -- | 189 | -- | 4,110 | -- | 123 | -- | 15,598 |
| 12-13 | -- | 1,601 | -- | 64 | -- | 1,504 | -- | 34 | -- | 5,116 |
| 14-15 | -- | 1,507 | -- | 82 | -- | 1,389 | -- | 36 | -- | 5,354 |
| 16-17 | -- | 1,314 | -- | 44 | -- | 1,217 | -- | 53 | -- | 5,128 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient substance use treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. NOTE: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used drugs or alcohol in their lifetime. NOTE: The substance use treatment measures have added uncertainty because of the high proportion of respondents in the “substance unspecified” category for substance use treatment. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. 1 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 2 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||
| Substance Use Disorder/MDE/Age Group | Received Substance Use Treatment (SU Tx) OR Mental Health Treatment (MH Tx) (2023) |
Received Substance Use Treatment (SU Tx) OR Mental Health Treatment (MH Tx) (2024) |
Received SU Tx BUT NOT MH Tx (2023) |
Received SU Tx BUT NOT MH Tx (2024) |
Received MH Tx BUT NOT SU Tx (2023) |
Received MH Tx BUT NOT SU Tx (2024) |
Received SU Tx AND MH Tx (2023) |
Received SU Tx AND MH Tx (2024) |
Received NEITHER SU Tx NOR MH Tx (2023) |
Received NEITHER SU Tx NOR MH Tx (2024) |
|---|---|---|---|---|---|---|---|---|---|---|
| Substance Use Disorder and MDE | -- | 72.1 | -- | 1.0 | -- | 53.0 | -- | 18.1 | -- | 27.9 |
| 12-13 | -- | * | -- | * | -- | * | -- | * | -- | * |
| 14-15 | -- | 72.4 | -- | 0.1 | -- | * | -- | 21.2 | -- | 27.6 |
| 16-17 | -- | 69.9 | -- | 0.4 | -- | 51.4 | -- | 18.1 | -- | 30.1 |
| Substance Use Disorder and MDE with Severe Impairment1,2 | -- | 73.9 | -- | 1.2 | -- | 52.2 | -- | 20.6 | -- | 26.1 |
| 12-13 | -- | * | -- | * | -- | * | -- | * | -- | * |
| 14-15 | -- | * | -- | * | -- | 41.4 | -- | 27.8 | -- | * |
| 16-17 | -- | 73.6 | -- | 0.5 | -- | 53.5 | -- | 19.6 | -- | 26.4 |
| Substance Use Disorder and No MDE | -- | 42.4 | -- | 4.0 | -- | 28.6 | -- | 9.8 | -- | 57.6 |
| 12-13 | -- | * | -- | * | -- | * | -- | 12.7 | -- | * |
| 14-15 | -- | 50.0 | -- | 5.2 | -- | 33.4 | -- | 11.4 | -- | 50.0 |
| 16-17 | -- | 33.8 | -- | 3.5 | -- | 21.8 | -- | 8.6 | -- | 66.2 |
| MDE and No Substance Use Disorder | -- | 58.5 | -- | 0.7 | -- | 56.1 | -- | 1.7 | -- | 41.5 |
| 12-13 | -- | 58.9 | -- | <0.1 | -- | 57.4 | -- | 1.4 | -- | 41.1 |
| 14-15 | -- | 59.9 | -- | 0.3 | -- | 57.1 | -- | 2.5 | -- | 40.1 |
| 16-17 | -- | 57.0 | -- | 1.4 | -- | 54.4 | -- | 1.2 | -- | 43.0 |
| No Substance Use Disorder and No MDE | -- | 22.1 | -- | 0.9 | -- | 20.5 | -- | 0.6 | -- | 77.9 |
| 12-13 | -- | 23.8 | -- | 0.9 | -- | 22.4 | -- | 0.5 | -- | 76.2 |
| 14-15 | -- | 22.0 | -- | 1.2 | -- | 20.2 | -- | 0.5 | -- | 78.0 |
| 16-17 | -- | 20.4 | -- | 0.7 | -- | 18.9 | -- | 0.8 | -- | 79.6 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient substance use treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. NOTE: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used drugs or alcohol in their lifetime. NOTE: The substance use treatment measures have added uncertainty because of the high proportion of respondents in the “substance unspecified” category for substance use treatment. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. NOTE: Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. NOTE: Respondents with unknown past year major depressive episode (MDE) data were excluded. 1 Major depressive episode (MDE) with severe impairment is a subset of MDE. Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on a person’s life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains indicate severe impairment. 2 Respondents with unknown MDE data or unknown impairment data were excluded. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||
| Demographic Characteristic | HAD SERIOUS THOUGHTS OF SUICIDE | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| TOTAL | 3,189b | 2,613 | 18,880b | 19,794 | 2,065a | 1,740 | 1,696 | 1,754 |
| AGE GROUP | ||||||||
| 12-13 | 641 | 661 | 6,066 | 6,229 | 607 | 540 | 607 | 651 |
| 14-15 | 1,325b | 917 | 6,442 | 6,731 | 711 | 612 | 631 | 587 |
| 16-17 | 1,223 | 1,035 | 6,371 | 6,834 | 747 | 588 | 458 | 516 |
| SEX | ||||||||
| Male | 1,038a | 831 | 10,729a | 11,056 | 802 | 665 | 633 | 687 |
| Female | 2,151b | 1,782 | 8,151b | 8,738 | 1,263 | 1,074 | 1,063 | 1,067 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | 2,377b | 1,972 | 13,864b | 14,478 | 1,503a | 1,242 | 1,313 | 1,321 |
| AIAN | 30 | 16 | 156 | 155 | 20 | 13 | 28 | * |
| Asian | 152 | 141 | 1,045 | 1,175 | 152 | 105 | 102 | 93 |
| Black or African American | 354 | 314 | 2,636 | 2,687 | 278 | 224 | 310 | 331 |
| NHPI | * | * | * | * | 3 | * | 3 | * |
| White | 1,675b | 1,347 | 9,353 | 9,701 | 959 | 807 | 798 | 758 |
| Two or More Races | 162 | 146 | 601 | 694 | 91 | 90 | 73 | 111 |
| Hispanic or Latino | 812 | 641 | 5,016a | 5,316 | 562 | 498 | 382 | 433 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | HAD SERIOUS THOUGHTS OF SUICIDE | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| TOTAL | 12.3b | 10.1 | 73.1b | 76.4 | 8.0a | 6.7 | 6.6 | 6.8 |
| AGE GROUP | ||||||||
| 12-13 | 8.1 | 8.2 | 76.6 | 77.1 | 7.7 | 6.7 | 7.7 | 8.1 |
| 14-15 | 14.5b | 10.4 | 70.7b | 76.1 | 7.8 | 6.9 | 6.9 | 6.6 |
| 16-17 | 13.9a | 11.5 | 72.4a | 76.2 | 8.5a | 6.6 | 5.2 | 5.8 |
| SEX | ||||||||
| Male | 7.9a | 6.3 | 81.3a | 83.5 | 6.1 | 5.0 | 4.8 | 5.2 |
| Female | 17.0b | 14.1 | 64.5b | 69.0 | 10.0 | 8.5 | 8.4 | 8.4 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | 12.5b | 10.4 | 72.7b | 76.1 | 7.9a | 6.5 | 6.9 | 6.9 |
| AIAN | 12.8 | 7.6 | 66.7 | 74.3 | 8.5 | 6.3 | 12.0 | * |
| Asian | 10.5 | 9.3 | 72.0 | 77.6 | 10.5 | 6.9 | 7.0 | 6.2 |
| Black or African American | 9.9 | 8.8 | 73.7 | 75.6 | 7.8 | 6.3 | 8.7 | 9.3 |
| NHPI | * | * | * | * | 3.2 | * | 3.2 | * |
| White | 13.1b | 10.7 | 73.2b | 76.9 | 7.5 | 6.4 | 6.2 | 6.0 |
| Two or More Races | 17.5 | 14.0 | 64.9 | 66.7 | 9.8 | 8.6 | 7.8 | 10.6 |
| Hispanic or Latino | 12.0a | 9.3 | 74.1 | 77.2 | 8.3 | 7.2 | 5.6 | 6.3 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | MADE ANY SUICIDE PLANS | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| TOTAL | 1,457b | 1,186 | 22,044b | 22,580 | 908b | 668 | 1,420 | 1,466 |
| AGE GROUP | ||||||||
| 12-13 | 265 | 327 | 6,915 | 6,995 | 278 | 198 | 463 | 560 |
| 14-15 | 656b | 385 | 7,559 | 7,683 | 337 | 295 | 557 | 484 |
| 16-17 | 536 | 474 | 7,570 | 7,902 | 294a | 176 | 400 | 422 |
| SEX | ||||||||
| Male | 377 | 356 | 11,929 | 12,051 | 356 | 263 | 539 | 570 |
| Female | 1,080b | 830 | 10,115b | 10,529 | 552a | 405 | 882 | 896 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | 1,046 | 923 | 16,240a | 16,550 | 672b | 444 | 1,099 | 1,096 |
| AIAN | 10 | 12 | 193 | 163 | 11 | 7 | 21 | * |
| Asian | 85 | 56 | 1,219 | 1,363 | 54 | 19 | 93 | 76 |
| Black or African American | 184 | 175 | 2,992 | 3,009 | 146a | 84 | 255 | 289 |
| NHPI | * | <1 | * | 79 | 1 | * | * | 1 |
| White | 684 | 601 | 11,035 | 11,093 | 422a | 294 | 645 | 624 |
| Two or More Races | 77 | 78 | 729 | 843 | 38 | 40 | 84 | 79 |
| Hispanic or Latino | 411a | 264 | 5,804a | 6,030 | 237 | 224 | 321 | 370 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | MADE ANY SUICIDE PLANS | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| TOTAL | 5.6b | 4.6 | 85.3b | 87.2 | 3.5b | 2.6 | 5.5 | 5.7 |
| AGE GROUP | ||||||||
| 12-13 | 3.3 | 4.0 | 87.3 | 86.6 | 3.5a | 2.4 | 5.8 | 6.9 |
| 14-15 | 7.2b | 4.4 | 83.0b | 86.8 | 3.7 | 3.3 | 6.1 | 5.5 |
| 16-17 | 6.1 | 5.3 | 86.0 | 88.1 | 3.3b | 2.0 | 4.5 | 4.7 |
| SEX | ||||||||
| Male | 2.9 | 2.7 | 90.4 | 91.0 | 2.7 | 2.0 | 4.1 | 4.3 |
| Female | 8.6b | 6.6 | 80.1b | 83.2 | 4.4a | 3.2 | 7.0 | 7.1 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | 5.5 | 4.9 | 85.2b | 87.0 | 3.5b | 2.3 | 5.8 | 5.8 |
| AIAN | 4.2 | 5.8 | 82.2 | 78.0 | 4.6 | 3.3 | 9.0 | * |
| Asian | 5.8 | 3.7 | 84.0a | 90.0 | 3.7 | 1.2 | 6.4 | 5.0 |
| Black or African American | 5.1 | 4.9 | 83.6 | 84.6 | 4.1a | 2.4 | 7.1 | 8.1 |
| NHPI | * | <0.1 | * | 96.7 | 1.2 | * | * | 1.6 |
| White | 5.3 | 4.8 | 86.3a | 88.0 | 3.3a | 2.3 | 5.0 | 4.9 |
| Two or More Races | 8.3 | 7.5 | 78.6 | 81.0 | 4.1 | 3.8 | 9.0 | 7.6 |
| Hispanic or Latino | 6.1a | 3.8 | 85.7 | 87.5 | 3.5 | 3.3 | 4.7 | 5.4 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | ATTEMPTED SUICIDE | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| TOTAL | 856a | 700 | 23,234a | 23,524 | 533 | 431 | 1,207 | 1,246 |
| AGE GROUP | ||||||||
| 12-13 | 185 | 210 | 7,211 | 7,241 | 143 | 136 | 382 | 493 |
| 14-15 | 385b | 219 | 8,057 | 8,085 | 179 | 174 | 489a | 369 |
| 16-17 | 286 | 271 | 7,966 | 8,198 | 210a | 121 | 337 | 384 |
| SEX | ||||||||
| Male | 207 | 220 | 12,312 | 12,327 | 215 | 198 | 468 | 495 |
| Female | 649b | 480 | 10,922a | 11,197 | 317 | 233 | 740 | 751 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | 631 | 529 | 17,135 | 17,200 | 372 | 301 | 918 | 983 |
| AIAN | 9 | 9 | 204 | 167 | 8 | 4 | 13 | * |
| Asian | 44 | 27 | 1,313 | 1,407 | 17 | 23 | 76 | 57 |
| Black or African American | 137 | 121 | 3,072 | 3,106 | 115 | 73 | 254 | 256 |
| NHPI | * | * | * | * | <1 | * | 2 | * |
| White | 395 | 333 | 11,676 | 11,524 | 204 | 169 | 510 | 587 |
| Two or More Races | 40 | 38 | 796 | 917 | 28 | 32 | 62 | 54 |
| Hispanic or Latino | 225 | 171 | 6,099b | 6,324 | 160 | 130 | 289 | 263 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | ATTEMPTED SUICIDE | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| TOTAL | 3.3a | 2.7 | 89.9 | 90.8 | 2.1 | 1.7 | 4.7 | 4.8 |
| AGE GROUP | ||||||||
| 12-13 | 2.3 | 2.6 | 91.0 | 89.6 | 1.8 | 1.7 | 4.8 | 6.1 |
| 14-15 | 4.2b | 2.5 | 88.4b | 91.4 | 2.0 | 2.0 | 5.4 | 4.2 |
| 16-17 | 3.3 | 3.0 | 90.5 | 91.4 | 2.4a | 1.3 | 3.8 | 4.3 |
| SEX | ||||||||
| Male | 1.6 | 1.7 | 93.3 | 93.1 | 1.6 | 1.5 | 3.5 | 3.7 |
| Female | 5.1b | 3.8 | 86.5a | 88.4 | 2.5 | 1.8 | 5.9 | 5.9 |
| HISPANIC ORIGIN AND RACE | ||||||||
| Not Hispanic or Latino | 3.3 | 2.8 | 89.9 | 90.5 | 2.0 | 1.6 | 4.8 | 5.2 |
| AIAN | 3.8 | 4.4 | 87.1 | 80.3 | 3.6 | 1.8 | 5.5 | * |
| Asian | 3.0 | 1.8 | 90.5 | 92.9 | 1.2 | 1.5 | 5.3 | 3.8 |
| Black or African American | 3.8 | 3.4 | 85.9 | 87.4 | 3.2 | 2.0 | 7.1 | 7.2 |
| NHPI | * | * | * | * | 0.6 | * | 2.9 | * |
| White | 3.1 | 2.6 | 91.3 | 91.4 | 1.6 | 1.3 | 4.0 | 4.7 |
| Two or More Races | 4.3 | 3.7 | 85.9 | 88.1 | 3.0 | 3.0 | 6.7 | 5.2 |
| Hispanic or Latino | 3.3 | 2.5 | 90.0 | 91.8 | 2.4 | 1.9 | 4.3 | 3.8 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Demographic Characteristic | HAD SERIOUS THOUGHTS OF SUICIDE, MADE ANY SUICIDE PLANS, OR ATTEMPTED SUICIDE | |||||
|---|---|---|---|---|---|---|
| Any of These Suicidality Measures | None of These Suicidality Measures | Unknown | ||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| TOTAL | 3,344b | 2,800 | 18,678b | 19,593 | 3,809 | 3,508 |
| AGE GROUP | ||||||
| 12-13 | 690 | 714 | 5,999 | 6,152 | 1,232 | 1,215 |
| 14-15 | 1,390b | 976 | 6,368 | 6,680 | 1,351 | 1,191 |
| 16-17 | 1,264 | 1,110 | 6,310 | 6,761 | 1,226 | 1,102 |
| SEX | ||||||
| Male | 1,097a | 893 | 10,654a | 10,937 | 1,451 | 1,409 |
| Female | 2,247b | 1,907 | 8,024b | 8,656 | 2,358 | 2,099 |
| HISPANIC ORIGIN AND RACE | ||||||
| Not Hispanic or Latino | 2,489b | 2,107 | 13,715b | 14,314 | 2,853 | 2,592 |
| AIAN | 31 | 18 | 153 | 149 | 51 | 41 |
| Asian | 160 | 153 | 1,034 | 1,172 | 256 | 188 |
| Black or African American | 374 | 345 | 2,597 | 2,645 | 605 | 567 |
| NHPI | * | * | * | * | 5 | * |
| White | 1,744b | 1,421 | 9,272 | 9,606 | 1,770 | 1,585 |
| Two or More Races | 171 | 161 | 589 | 675 | 166 | 205 |
| Hispanic or Latino | 855 | 693 | 4,963a | 5,279 | 955 | 916 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: The “any of these suicidality measures” category includes respondents with one or more “yes” responses to suicidal thoughts, plans, or attempts, regardless of whether they had one or more unknown responses for these measures. The “none of these suicidality measures” category includes respondents with “no” responses to all three measures. The “unknown” category includes respondents who did not respond “yes” to any of the three suicidality questions and who responded “not sure/don’t know” or “don’t want to answer/refuse” to any of the three suicidality questions. Respondents with unknown suicide data other than these categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Demographic Characteristic | HAD SERIOUS THOUGHTS OF SUICIDE, MADE ANY SUICIDE PLANS, OR ATTEMPTED SUICIDE | |||||
|---|---|---|---|---|---|---|
| Any of These Suicidality Measures | None of These Suicidality Measures | Unknown | ||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| TOTAL | 12.9b | 10.8 | 72.3b | 75.6 | 14.7 | 13.5 |
| AGE GROUP | ||||||
| 12-13 | 8.7 | 8.8 | 75.7 | 76.1 | 15.5 | 15.0 |
| 14-15 | 15.3b | 11.0 | 69.9b | 75.5 | 14.8 | 13.5 |
| 16-17 | 14.4 | 12.4 | 71.7a | 75.3 | 13.9 | 12.3 |
| SEX | ||||||
| Male | 8.3a | 6.7 | 80.7 | 82.6 | 11.0 | 10.6 |
| Female | 17.8b | 15.1 | 63.5b | 68.4 | 18.7 | 16.6 |
| HISPANIC ORIGIN AND RACE | ||||||
| Not Hispanic or Latino | 13.1b | 11.1 | 72.0b | 75.3 | 15.0 | 13.6 |
| AIAN | 13.2 | 8.5 | 65.2 | 71.7 | 21.7 | 19.7 |
| Asian | 11.0 | 10.1 | 71.3 | 77.5 | 17.6 | 12.4 |
| Black or African American | 10.5 | 9.7 | 72.6 | 74.4 | 16.9 | 15.9 |
| NHPI | * | * | * | * | 6.2 | * |
| White | 13.6b | 11.3 | 72.5b | 76.2 | 13.8 | 12.6 |
| Two or More Races | 18.5 | 15.5 | 63.6 | 64.9 | 17.9 | 19.7 |
| Hispanic or Latino | 12.6 | 10.1 | 73.3 | 76.6 | 14.1 | 13.3 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: The “any of these suicidality measures” category includes respondents with one or more “yes” responses to suicidal thoughts, plans, or attempts, regardless of whether they had one or more unknown responses for these measures. The “none of these suicidality measures” category includes respondents with “no” responses to all three measures. The “unknown” category includes respondents who did not respond “yes” to any of the three suicidality questions and who responded “not sure/don’t know” or “don’t want to answer/refuse” to any of the three suicidality questions. Respondents with unknown suicide data other than these categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||
| Past Year Mental Health or Substance Use Measure | HAD SERIOUS THOUGHTS OF SUICIDE | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| MAJOR DEPRESSIVE EPISODE1 | ||||||||
| Major Depressive Episode | 2,031b | 1,559 | 1,306 | 1,262 | 667a | 523 | 513 | 497 |
| No Major Depressive Episode | 1,094 | 964 | 17,145 | 18,158 | 1,232 | 1,042 | 898 | 964 |
| MENTAL HEALTH TREATMENT AND PERCEIVED UNMET NEED FOR TREATMENT2 | ||||||||
| Mental Health Treatment | -- | 1,597 | -- | 4,302 | -- | 766 | -- | 724 |
| No Mental Health Treatment | -- | 1,016 | -- | 15,492 | -- | 974 | -- | 1,030 |
| Perceived Unmet Need for Treatment3 | -- | 423 | -- | 846 | -- | 237 | -- | 209 |
| Did Not Seek Treatment and Did Not Think Should Get Treatment3 | -- | 587 | -- | 14,487 | -- | 681 | -- | 754 |
| SUBSTANCE USE DISORDER4 | ||||||||
| Substance Use Disorder | 710 | 712 | 1,056 | 931 | 245 | 189 | 166 | 188 |
| Alcohol Use Disorder | 254 | 314 | 380 | 304 | 69 | 80 | 47 | 77 |
| Drug Use Disorder | 616 | 616 | 809 | 776 | 206 | 162 | 138 | 149 |
| No Substance Use Disorder | 2,479b | 1,901 | 17,824 | 18,862 | 1,820 | 1,551 | 1,530 | 1,566 |
| SUBSTANCE USE TREATMENT5,6 | ||||||||
| Substance Use Treatment | -- | 201 | -- | 345 | -- | 86 | -- | 97 |
| No Substance Use Treatment | -- | 2,412 | -- | 19,449 | -- | 1,654 | -- | 1,657 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient substance use treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. 3 Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. 4 Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. 5 Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used drugs or alcohol in their lifetime. 6 The substance use treatment measures have added uncertainty because of the high proportion of respondents in the “substance unspecified” category for substance use treatment. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Past Year Mental Health or Substance Use Measure | HAD SERIOUS THOUGHTS OF SUICIDE | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| MAJOR DEPRESSIVE EPISODE1 | ||||||||
| Major Depressive Episode | 45.0 | 40.6 | 28.9 | 32.9 | 14.8 | 13.6 | 11.3 | 12.9 |
| No Major Depressive Episode | 5.4 | 4.6 | 84.2a | 85.9 | 6.0a | 4.9 | 4.4 | 4.6 |
| MENTAL HEALTH TREATMENT AND PERCEIVED UNMET NEED FOR TREATMENT2 | ||||||||
| Mental Health Treatment | -- | 21.6 | -- | 58.2 | -- | 10.4 | -- | 9.8 |
| No Mental Health Treatment | -- | 5.5 | -- | 83.7 | -- | 5.3 | -- | 5.6 |
| Perceived Unmet Need for Treatment3 | -- | 24.7 | -- | 49.3 | -- | 13.8 | -- | 12.2 |
| Did Not Seek Treatment and Did Not Think Should Get Treatment3 | -- | 3.6 | -- | 87.8 | -- | 4.1 | -- | 4.6 |
| SUBSTANCE USE DISORDER4 | ||||||||
| Substance Use Disorder | 32.6 | 35.2 | 48.5 | 46.1 | 11.3 | 9.4 | 7.6 | 9.3 |
| Alcohol Use Disorder | 33.9 | 40.5 | 50.6a | 39.2 | 9.2 | 10.4 | 6.3 | 9.9 |
| Drug Use Disorder | 34.8 | 36.2 | 45.7 | 45.6 | 11.6 | 9.5 | 7.8 | 8.7 |
| No Substance Use Disorder | 10.5b | 8.0 | 75.4b | 79.0 | 7.7a | 6.5 | 6.5 | 6.6 |
| SUBSTANCE USE TREATMENT5,6 | ||||||||
| Substance Use Treatment | -- | 27.6 | -- | 47.4 | -- | 11.8 | -- | 13.3 |
| No Substance Use Treatment | -- | 9.6 | -- | 77.3 | -- | 6.6 | -- | 6.6 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient substance use treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. 3 Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. 4 Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. 5 Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used drugs or alcohol in their lifetime. 6 The substance use treatment measures have added uncertainty because of the high proportion of respondents in the “substance unspecified” category for substance use treatment. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Past Year Mental Health or Substance Use Measure | MADE ANY SUICIDE PLANS | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| MAJOR DEPRESSIVE EPISODE1 | ||||||||
| Major Depressive Episode | 989a | 761 | 2,619 | 2,388 | 372a | 245 | 537 | 445 |
| No Major Depressive Episode | 436 | 375 | 18,850 | 19,684 | 428a | 286 | 655 | 782 |
| MENTAL HEALTH TREATMENT AND PERCEIVED UNMET NEED FOR TREATMENT2 | ||||||||
| Mental Health Treatment | -- | 758 | -- | 5,663 | -- | 326 | -- | 642 |
| No Mental Health Treatment | -- | 428 | -- | 16,917 | -- | 343 | -- | 824 |
| Perceived Unmet Need for Treatment3 | -- | 203 | -- | 1,260 | -- | 79 | -- | 172 |
| Did Not Seek Treatment and Did Not Think Should Get Treatment3 | -- | 224 | -- | 15,460 | -- | 229 | -- | 595 |
| SUBSTANCE USE DISORDER4 | ||||||||
| Substance Use Disorder | 444 | 413 | 1,429 | 1,339 | 121 | 99 | 184 | 170 |
| Alcohol Use Disorder | 170 | 190 | 491 | 462 | 31 | 48 | 58 | 74 |
| Drug Use Disorder | 385 | 376 | 1,126 | 1,128 | 109 | 71 | 148 | 127 |
| No Substance Use Disorder | 1,013b | 773 | 20,616 | 21,242 | 787b | 569 | 1,237 | 1,297 |
| SUBSTANCE USE TREATMENT5,6 | ||||||||
| Substance Use Treatment | -- | 125 | -- | 474 | -- | 40 | -- | 89 |
| No Substance Use Treatment | -- | 1,061 | -- | 22,107 | -- | 628 | -- | 1,377 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient substance use treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. 3 Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. 4 Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. 5 Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used drugs or alcohol in their lifetime. 6 The substance use treatment measures have added uncertainty because of the high proportion of respondents in the “substance unspecified” category for substance use treatment. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Past Year Mental Health or Substance Use Measure | MADE ANY SUICIDE PLANS | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| MAJOR DEPRESSIVE EPISODE1 | ||||||||
| Major Depressive Episode | 21.9 | 19.8 | 58.0a | 62.2 | 8.2 | 6.4 | 11.9 | 11.6 |
| No Major Depressive Episode | 2.1 | 1.8 | 92.5 | 93.2 | 2.1b | 1.4 | 3.2 | 3.7 |
| MENTAL HEALTH TREATMENT AND PERCEIVED UNMET NEED FOR TREATMENT2 | ||||||||
| Mental Health Treatment | -- | 10.3 | -- | 76.6 | -- | 4.4 | -- | 8.7 |
| No Mental Health Treatment | -- | 2.3 | -- | 91.4 | -- | 1.9 | -- | 4.5 |
| Perceived Unmet Need for Treatment3 | -- | 11.9 | -- | 73.5 | -- | 4.6 | -- | 10.0 |
| Did Not Seek Treatment and Did Not Think Should Get Treatment3 | -- | 1.4 | -- | 93.7 | -- | 1.4 | -- | 3.6 |
| SUBSTANCE USE DISORDER4 | ||||||||
| Substance Use Disorder | 20.4 | 20.5 | 65.6 | 66.2 | 5.6 | 4.9 | 8.4 | 8.4 |
| Alcohol Use Disorder | 22.6 | 24.6 | 65.5 | 59.7 | 4.1 | 6.3 | 7.8 | 9.5 |
| Drug Use Disorder | 21.8 | 22.1 | 63.7 | 66.3 | 6.2 | 4.2 | 8.4 | 7.5 |
| No Substance Use Disorder | 4.3b | 3.2 | 87.2b | 89.0 | 3.3b | 2.4 | 5.2 | 5.4 |
| SUBSTANCE USE TREATMENT5,6 | ||||||||
| Substance Use Treatment | -- | 17.1 | -- | 65.0 | -- | 5.6 | -- | 12.3 |
| No Substance Use Treatment | -- | 4.2 | -- | 87.8 | -- | 2.5 | -- | 5.5 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient substance use treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. 3 Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. 4 Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. 5 Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used drugs or alcohol in their lifetime. 6 The substance use treatment measures have added uncertainty because of the high proportion of respondents in the “substance unspecified” category for substance use treatment. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Past Year Mental Health or Substance Use Measure | ATTEMPTED SUICIDE | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| MAJOR DEPRESSIVE EPISODE1 | ||||||||
| Major Depressive Episode | 591b | 394 | 3,298a | 2,922 | 217 | 145 | 411 | 378 |
| No Major Depressive Episode | 243 | 279 | 19,330 | 20,003 | 225 | 182 | 571 | 663 |
| MENTAL HEALTH TREATMENT AND PERCEIVED UNMET NEED FOR TREATMENT2 | ||||||||
| Mental Health Treatment | -- | 467 | -- | 6,144 | -- | 200 | -- | 577 |
| No Mental Health Treatment | -- | 233 | -- | 17,380 | -- | 231 | -- | 669 |
| Perceived Unmet Need for Treatment3 | -- | 88 | -- | 1,472 | -- | 32 | -- | 122 |
| Did Not Seek Treatment and Did Not Think Should Get Treatment3 | -- | 144 | -- | 15,704 | -- | 175 | -- | 485 |
| SUBSTANCE USE DISORDER4 | ||||||||
| Substance Use Disorder | 286 | 280 | 1,623 | 1,482 | 96 | 75 | 172 | 184 |
| Alcohol Use Disorder | 107 | 139 | 582 | 526 | 17 | 30 | 44 | 80 |
| Drug Use Disorder | 247 | 240 | 1,280 | 1,257 | 93 | 56 | 148 | 148 |
| No Substance Use Disorder | 570a | 420 | 21,612 | 22,042 | 436 | 356 | 1,035 | 1,062 |
| SUBSTANCE USE TREATMENT5,6 | ||||||||
| Substance Use Treatment | -- | 110 | -- | 516 | -- | 20 | -- | 82 |
| No Substance Use Treatment | -- | 590 | -- | 23,008 | -- | 411 | -- | 1,164 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient substance use treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. 3 Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. 4 Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. 5 Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used drugs or alcohol in their lifetime. 6 The substance use treatment measures have added uncertainty because of the high proportion of respondents in the “substance unspecified” category for substance use treatment. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Past Year Mental Health or Substance Use Measure | ATTEMPTED SUICIDE | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Not Sure/Don’t Know | Don’t Want to Answer/Refuse | |||||
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| MAJOR DEPRESSIVE EPISODE1 | ||||||||
| Major Depressive Episode | 13.1 | 10.3 | 73.0 | 76.1 | 4.8 | 3.8 | 9.1 | 9.8 |
| No Major Depressive Episode | 1.2 | 1.3 | 94.9 | 94.7 | 1.1 | 0.9 | 2.8 | 3.1 |
| MENTAL HEALTH TREATMENT AND PERCEIVED UNMET NEED FOR TREATMENT2 | ||||||||
| Mental Health Treatment | -- | 6.3 | -- | 83.2 | -- | 2.7 | -- | 7.8 |
| No Mental Health Treatment | -- | 1.3 | -- | 93.9 | -- | 1.2 | -- | 3.6 |
| Perceived Unmet Need for Treatment3 | -- | 5.2 | -- | 85.9 | -- | 1.9 | -- | 7.1 |
| Did Not Seek Treatment and Did Not Think Should Get Treatment3 | -- | 0.9 | -- | 95.1 | -- | 1.1 | -- | 2.9 |
| SUBSTANCE USE DISORDER4 | ||||||||
| Substance Use Disorder | 13.2 | 13.8 | 74.5 | 73.3 | 4.4 | 3.7 | 7.9 | 9.1 |
| Alcohol Use Disorder | 14.3 | 17.9 | 77.6a | 67.9 | 2.2 | 3.8 | 5.9 | 10.3 |
| Drug Use Disorder | 14.0 | 14.1 | 72.4 | 73.9 | 5.3 | 3.3 | 8.3 | 8.7 |
| No Substance Use Disorder | 2.4a | 1.8 | 91.4 | 92.3 | 1.8 | 1.5 | 4.4 | 4.4 |
| SUBSTANCE USE TREATMENT5,6 | ||||||||
| Substance Use Treatment | -- | 15.1 | -- | 70.9 | -- | 2.8 | -- | 11.3 |
| No Substance Use Treatment | -- | 2.3 | -- | 91.4 | -- | 1.6 | -- | 4.6 |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: Changes were made to the inpatient and outpatient substance use treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: Changes were made to the inpatient and outpatient mental health treatment questions in 2024. See Chapter 3 of the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. 1 Major depressive episode aligns with DSM-5 criteria, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. 2 Mental health treatment includes treatment for mental health, emotions, or behavior through inpatient treatment/counseling; outpatient treatment/counseling; use of prescription medication; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. 3 Respondents were classified as having a perceived unmet need for mental health treatment (MH Tx) if they did not receive MH Tx in the past year and sought or thought they should get treatment. Respondents with unknown information for perceptions of need for MH Tx were excluded. 4 Substance use disorder is based on DSM-5 criteria. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details on who was eligible to receive questions on substance use disorder. 5 Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used drugs or alcohol in their lifetime. 6 The substance use treatment measures have added uncertainty because of the high proportion of respondents in the “substance unspecified” category for substance use treatment. See the 2024 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions for details. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||
| Suicidal Behavior/Treatment for Suicide Attempt | Aged 12-17 (2023) |
Aged 12-17 (2024) |
Aged 12-13 (2023) |
Aged 12-13 (2024) |
Aged 14-15 (2023) |
Aged 14-15 (2024) |
Aged 16-17 (2023) |
Aged 16-17 (2024) |
Male (2023) |
Male (2024) |
Female (2023) |
Female (2024) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATTEMPTED SUICIDE | ||||||||||||
| Yes | 856a | 700 | 185 | 210 | 385b | 219 | 286 | 271 | 207 | 220 | 649b | 480 |
| No | 23,234a | 23,524 | 7,211 | 7,241 | 8,057 | 8,085 | 7,966 | 8,198 | 12,312 | 12,327 | 10,922a | 11,197 |
| Not Sure/Don’t Know | 533 | 431 | 143 | 136 | 179 | 174 | 210a | 121 | 215 | 198 | 317 | 233 |
| Don’t Want to Answer/Refuse | 1,207 | 1,246 | 382 | 493 | 489a | 369 | 337 | 384 | 468 | 495 | 740 | 751 |
| RECEIVED MEDICAL ATTENTION FOR SUICIDE ATTEMPT AMONG PEOPLE WHO ATTEMPTED SUICIDE | ||||||||||||
| Yes | 363 | 284 | * | * | 169 | * | 119 | 96 | * | * | 269a | 172 |
| No | 440 | 387 | * | * | 195 | * | * | 169 | * | * | 353 | 285 |
| Not Sure/Don’t Know | 26 | 8 | 5 | * | * | * | * | 1 | * | * | 7 | 6 |
| Don’t Want to Answer/Refuse | 27 | 21 | 5 | * | 15 | 6 | * | 4 | 6 | 4 | 21 | 17 |
| STAYED OVERNIGHT OR LONGER IN A HOSPITAL FOR SUICIDE ATTEMPT AMONG PEOPLE WHO ATTEMPTED SUICIDE | ||||||||||||
| Yes | 199 | 177 | 36 | * | 93a | 39 | 70 | 80 | * | * | 133 | 100 |
| No | 603 | 486 | 139 | * | 271a | 167 | 194 | 185 | * | * | 488a | 349 |
| Not Sure/Don’t Know | * | 3 | * | * | * | * | * | * | * | * | * | 3 |
| Don’t Want to Answer/Refuse | 1 | * | 1 | * | * | <1 | * | * | * | * | 1 | * |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||||
| Suicidal Behavior/Treatment for Suicide Attempt | Aged 12-17 (2023) |
Aged 12-17 (2024) |
Aged 12-13 (2023) |
Aged 12-13 (2024) |
Aged 14-15 (2023) |
Aged 14-15 (2024) |
Aged 16-17 (2023) |
Aged 16-17 (2024) |
Male (2023) |
Male (2024) |
Female (2023) |
Female (2024) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATTEMPTED SUICIDE | ||||||||||||
| Yes | 3.3a | 2.7 | 2.3 | 2.6 | 4.2b | 2.5 | 3.3 | 3.0 | 1.6 | 1.7 | 5.1b | 3.8 |
| No | 89.9 | 90.8 | 91.0 | 89.6 | 88.4b | 91.4 | 90.5 | 91.4 | 93.3 | 93.1 | 86.5a | 88.4 |
| Not Sure/Don’t Know | 2.1 | 1.7 | 1.8 | 1.7 | 2.0 | 2.0 | 2.4a | 1.3 | 1.6 | 1.5 | 2.5 | 1.8 |
| Don’t Want to Answer/Refuse | 4.7 | 4.8 | 4.8 | 6.1 | 5.4 | 4.2 | 3.8 | 4.3 | 3.5 | 3.7 | 5.9 | 5.9 |
| RECEIVED MEDICAL ATTENTION FOR SUICIDE ATTEMPT AMONG PEOPLE WHO ATTEMPTED SUICIDE | ||||||||||||
| Yes | 42.4 | 40.6 | * | * | 44.0 | * | 41.6 | 35.6 | * | * | 41.4 | 35.9 |
| No | 51.4 | 55.3 | * | * | 50.6 | * | * | 62.4 | * | * | 54.3 | 59.4 |
| Not Sure/Don’t Know | 3.1 | 1.1 | 2.5 | * | * | * | * | 0.5 | * | * | 1.0 | 1.2 |
| Don’t Want to Answer/Refuse | 3.1 | 3.0 | 2.8 | * | 3.9 | 2.6 | * | 1.5 | 2.8 | 2.0 | 3.2 | 3.5 |
| STAYED OVERNIGHT OR LONGER IN A HOSPITAL FOR SUICIDE ATTEMPT AMONG PEOPLE WHO ATTEMPTED SUICIDE | ||||||||||||
| Yes | 24.8 | 26.4 | 20.7 | * | 25.5 | 18.6 | 26.5 | 30.1 | * | * | 21.4 | 21.8 |
| No | 75.1 | 72.4 | 79.0 | * | 74.5 | 79.8 | 73.5 | 69.9 | * | * | 78.5 | 76.4 |
| Not Sure/Don’t Know | * | 0.4 | * | * | * | * | * | * | * | * | * | 0.7 |
| Don’t Want to Answer/Refuse | 0.1 | * | 0.3 | * | * | 0.2 | * | * | * | * | 0.1 | * |
| * = low precision; -- = not available or not comparable due to methodological or questionnaire changes; da = does not apply; nr = not reported due to measurement issues. NOTE: For youth suicidality measures, responses of “Yes,” “No,” “Not Sure,” “Don’t Know,” “Don’t Want to Answer,” and “Refuse” are categorized as valid, known data. Respondents with unknown suicidality data for other categories were excluded. a,b The difference between this estimate and the 2024 estimate is statistically significant at the .05 level (a) or .01 level (b). Rounding may make the estimates appear identical. Definitions: Measures and terms are defined in Appendix A. Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2023 and 2024. |
||||||||||||
